- Babli Thakur
- Mahendra Singh Ashawat
- Pravin Kumar
- Harika Cherukuri
- K. Pramoda
- D. Rohini
- Girish Thunga
- K. Vijaynarayana
- N. Sreedharan
- Muralidhar Varma
- Tejasavi Mahajan
- Navdeep Singh
- Kamya Goyal
- Shammy Jindal
- M.S. Ashawat
- Anshul Sharma
- Keshav Dhiman
- M. S. Ashawat
- Sweta
- Archana Chaudhary
- Tarun Kumar
- Neha Sharma
- Tarun Kumar Sharma
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Pandit, Vinay
- Natural and Synthetic Polymers for Colon Targeted Drug Delivery
Authors
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Kangra (H.P)-177101, IN
Source
Asian Journal of Pharmacy and Technology, Vol 6, No 1 (2016), Pagination: 35-44Abstract
Colon targeted drug delivery system have recently gained importance in delivery of number of therapeutic agents for both local and systemic action. Colon targeted drug delivery system is useful for delivery of proteins and peptides, drugs undergoing degradation in stomach and small intestine. Targeting of drugs to colon is also favorable for the chronotherapy of diseases. To achieve successful, colonic delivery, a drug is needed to be protected from absorption in upper gastrointestinal tract (GIT). Out of the several approaches for colon targeting, coating the drug core with a polymer or polymer combinations is an important strategy. Coating of drug core with a pH dependent polymer or a polymer biodegraded in colon by colonic flora has been widely investigated approach for colonic delivery. Polysaccharides are important polymers from either natural or synthetic origin which have been exhaustively studied for successful colon targeting. This review describes some important natural and synthetic polysaccharides and polymers investigated for colonic drug delivery by coating the drug core.Keywords
Colon, Polymer, Coating, Biodegradation, Polysaccharide.- Demographics, Clinical Characteristics and Management of Herbicide Poisoning in Tertiary Care Hospital
Authors
Source
Toxicology International (Formerly Indian Journal of Toxicology), Vol 21, No 2 (2014), Pagination: 209-213Abstract
Herbicide poisoning is most common method of suicide in India and it is associated with high morbidity and mortality. Among different herbicidal poisonings the most predominantly found poisonings are paraquat and glyphosate. These compounds are highly toxic and their poisonings require proper management techniques. High fatality is seen in these cases which are mainly due to its inherent toxicity and lack of effective treatment. Common symptoms of these poisonings includes gastrointestinal corrosive effects with mouth and throat, epigastric pain and dysphagia, acid‑base imbalance, pulmonary edema, shock and arrhythmia. Long term health effects include pulmonary fibrosis, renal failure, hepatic failure, heart failure, multi‑organ failure or death. No proven antidote exists for these poisonings. So the treatment is mainly supportive. Initially gastric lavage or whole‑gut irrigation using adsorbents such as Fuller’s earth, bentonite or activated charcoal is recommended. In case of renal failure hemodialysis or hemoperfusion may be considered. However novel approaches like treatment with N‑acetylcysteine, vitamin C, vitamin E, cyclophosphamide may also be helpful.Keywords
Glyphosate, herbicide, poisoning, paraquat, treatment- Gold Nanoparticle-Small Drug Molecule Conjugates:Therapeutic Applications and Benefits as Compared to Free Drug
Authors
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kangra, H. P., IN
Source
Asian Journal of Pharmacy and Technology, Vol 8, No 1 (2018), Pagination: 52-62Abstract
Gold nanoparticles (AuNPs) have been profoundly investigated for drug delivery applications. Various widely used small drugs molecules when conjugated either covalently or non-covalently with the AuNPs, showed improved therapeutic effect with reduced dose and adverse effects as compared to drug alone. This review focuses on therapeutic efficiency of AuNPs-small drug molecule conjugates as anti-cancer, anti-bacterial, antiretroviral and anti-arthritic agents. The basic approaches of conjugation, brief of procedure followed for activity determination and mechanism of action of conjugates have also been discussed.Keywords
Gold, Nanoparticles, Drug Conjugates, Anti-Cancer, Anti-Bacterial, Drug Delivery.References
- Farady M. Experimental relations of gold (and other metals) to light. Phil Trans R Soc London. 1875; 14: 145-81.
- Kumar D, Saini N, Jain N, Sareen R, Pandit V. Gold nanoparticles: an era in bionanotechnology. Expert Opin Drug Delivery.
- Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell - mediated near infra-red thermal therapy of tumors under magnetic resonance guide. ProcNatlAcadSci USA. 2003; 100: 13549-54.
- Christopher LB, Bushell G, et al. Nanogold pharmaceutics. Gold bulletin. 2007; 40: 245.
- Leonaviciene L, Kirdaite R, et al. Effect of gold nanoparticles in the treatment of established collagen arthritis in rats. Medicinia (Kaunas). 2012; 48: 91.
- Li X, Robinson SM, Gupta A, Saha K, Jiang Z, Moyano DF et al. Functional gold nanoparticles as potent antimicrobial agents against multi drug resistant bacteria. ACS Nano. DOI: 10.1021/nn5042625
- Venkatachalam M, Govindaraju K, Mohamed Sadiq A, Tamilselvan S, Ganesh Kumar V, Singaravelu G. Functionalization of gold nanoparticles as anti-diabetic nanomaterial. Spectrochim Acta A Mol Biomol Spectrosc. 2013; 116: 331-38.
- Daisy P, Saipriya K. Biochemical analysis of Cassia fistula aqueous extract and phytochemically synthesized gold nanoparticles as hypoglycemic treatment for diabetes mellitus. Int J Nanomedicine. 2012; 7: 1189-1202.
- Vigderman L, Zubarev ER. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv Drug Del Rev. 2013; 65: 663-676.
- Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applicatons. Adv Drug Del Rev. 2008; 60: 1307-15.
- Bhumkar DR, Joshi HM, Sastry M, Pokharkar VB. Chitosan reduced gold nanoparticles as novel carrier for transmucosal delivery of insulin. Pharm Res. 2007; 24: 1415-26.
- Oshi M, Nakaogami J, Ishii T, Nagasaki Y. Smart PEGylated gold nanoparticles for the cytoplasmic delivery of s-RNA to induce enhanced gene silencing. ChemLett. 2006; 35: 1046-47.
- Wang H, Chen Y, Li XY, Liu Y. Synthesis of oligo(ethylenediamino)-β-cyclodextrn modified gold nanoparticle as a DNA concentrator. Mol Pharm. 2007; 4: 189-98.
- Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles.ProcNatlAcad Sci. 2008; 105: 17356-61.
- Dhar S, Liu Z, Thomale JE, Dai H, Lippard SJ. Targeted singlewall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc. 2008; 130: 11467-76.
- Feazell RP, Nakayama-Ratchford N, Dai H, Lippard SJ. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc. 2007; 129: 8438–39.
- Dhar S, Daniel WL, Giljohann DA, Mirkin CA, Lippard SJ. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum (IV) warheads. J Am Chem Soc. 2009; 131: 14652-53.
- Min Y, Mao C, Xu D, Wang J, Liu Y. Gold nanorods for platinum based prodrug delivery. Chem Commun. 2010; 46: 8424-26.
- Patra CR, Bhattacharya R, Mukherjee P. Fabricatin and functional characterization of gold nanoconjugates for potential application in ovarian cancer. J Mater Chem. 2010; 20 (3): 547-53.
- Brown SD, Nativo P, Smith JA, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 2010; 132 (13): 4678-84. doi: 10.1021/ja908117a.
- C Senthil Kumar MD, Raja D, SatihishSundar M, Grover Antoniraj K Rukmani. Hyaluronic aacid co-functionalized gold nanoparticle for targeted delivery of metformin in the treatment of liver cancer (HepG2 cells). Carbohydrate polymer. http://dx.doi.org/doi:10.1016/j.carbpol.2015.04.010
- Joshi P, Chakaraborty S, Dey S, Shanker V, Ansari ZA, Singh SP, Chakrabarti P. Binding of chloroquine conjugated gold nanoparticles with bovine serum albumin. Journal of colloid and interface science. 2011; 355: 402-9.
- KhaingOo MK, Yang X, Du H, Wang H. 5-amino levulinic acid conjugated gold nanoparticles for photodynamic therapy of cancer. Nanomedicine. 2008; 2: 12-15.
- Chen YH, Tsai CY, Huang PY, Chang MY, Cheng PC, Chou CH et al. Methotrexate conjugated to gold nanoparticles inhibits tumor growth in syngeneic lung tumor model. Mol Pharmaceutics. 2007; 4 (5): 713-22.
- Murawala P, Tirmale A, Shiras A, Prasad BLV. In situ synthesized BSA capped gold nanoparticles: Effective carrier of anticancer drug Methotrexate to MCF-7 breast cancer cells. Materials Science and Engineering. 2014; 34: 158-67.
- Podsiadlo P, Sinani VA, Bahng JH, Kam NWS, Lee J, Kotov NA. Gold nanoparticles enhance the anti-leukemia action of a 6-mercaptopurinechemotherapeutic agent. Langmuir. 2008; 24: 568-74.
- Gibson JD, Khanal BP, Zubarev ER. Paclitaxel-functionalized gold nanoparticles. J Am Chem Soc. 2007; 129 (37): 11653-61.
- Hwu JR, Lin YS, Josephrajan T, Hsu MH, Cheng FY, Yeh CS, Su DC, Shieh DB. Targeted paclitaxel by conjugation to iron oxide and gold nanoparticles. J Am Chem Soc. 2008; 131: 66-68.
- Zhang XQ, Xu X, Lam R, Giljohann D, Ho D, Mirkin CA. Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA nanoparticle conjugates. ACS Nano. 2011; 5 (9): 6962-70.
- Heo DN, Yang DH, Moon HJ, Lee JB, Bae MS, Lee SC, Lee WJ, Sun IC, Kwon KI. Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomaterial. 2012; 33: 856-66.
- Wang F, Wang FC, Dou S, Xiong MH, Sun TM, Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano. 2011; 5: 3679-92.
- Bae Y, Fukushima S, Harada A, Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew ChemInt Ed. 2003; 42: 4640-43.
- Kim B, Han G, Toley B, Kim CK, Rotello VM, Forbes NS. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat Nanotechnol. 2010; 5 (6): 465-72.
- Shirazi AN, Mandal D, Tiwari RK, Guao L, Lu W, Parang K. Cyclic peptide capped gold nanoparticles as drug delivery systems. Mol Pharmaceutics. 2013; 10 (2): 500-511.
- Agasti SS, Chompoosor A, You CC, Ghosh P, Kim CK, Rotello VM. Photoregulated release of caged anticancer drugs from gold nanoparticles. J Am Chem Soc. 2009; 131 (16): 5728-29.
- Dreaden EC, Mwakwari SC, Sodji QH, Oyelere AK, El-Sayed MA. Tamoxifen poly(ethylene glycol) thiol gold nanoparticle conjugates: enhanced potency andselective delivery for breast cancer treatment. Bioconjugate Chem. 2009; 20 (12): 2247-53.
- Hosta L, Pla-Roca M, Arbiol J, Lo¦üpez-Iglesias C, Samitier J, Cruz LZ, Kogan MJ, Albericio F, Conjugation of kahalalide F with gold nanoparticles to enhance in vitro antitumoral activity. Bioconjugate Chem. 2008: 20: 138-46.
- Kim CK, Ghosh P, Pagliuca C, Zhu ZJ, Menichetti S, Rotello VM. Entrapment of hydrophobic drugs in nanoparticle monolayers with efficient release into cancer cells. J Am Chem Soc. 2009; 131 (4): 1360-61.
- Cheng Y, Samia AC, Meyers JD, Panagopoulos I, Fei B, Burda C. Highly efficient drug delivery with gold nanoparticle vectors for in vivophotodynamic therapy of cancer. J Am Chem Soc. 2008; 130 (32): 10643-47.
- Dixit SK, Zhu Y, Moore A, Kenney M, Broome AM. Doubletargeted theranostic gold nanoparticles for treatment of brain tumors. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5413. doi:10.1158/1538-7445.AM2014-5413.
- Tomuleasa C, Soritau O, Orza A, Dudea M, Petrushev B, Mosteanu O, Susman S, Florea A, Pall E, Aldea M, Kacso G, Cristea V, Berindan-Neagoe I, Irimie A. Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells. J Gastro Intestin Liver Dis. 2012; 21 (2): 187-96.
- Grace AN, Pandian K. Antibacterial efficacy of aminoglycosidic antibiotics protected gold nanoparticles brief study. Colloids Surf. 2007; A 297: 63–70.
- Grace AN, Pandian K. Quinolone antibiotic-capped gold nanoparticles and their antibacterial efficacy against gram positive and gram negative organisms. J Bionanosci. 2007; 1: 96-105.
- Saha B, Bhattacharya J, Mukherjee A, Ghosh A, Santra C, Dasgupta A, Karmakar P. in vitro structural and functional evaluation of gold nanoparticles conjugated antibiotics.Nanoscale Res Lett.2007; 2: 614-22.
- Burygin GL, Khlebtsov BN, Shantrokha AN, Dykman LA, Bogatyrev VA, Khlebtsov NG. On the enhanced antibacterial activity of antibiotics mixed with goldnanoparticles. Nanoscale Res Lett. 2009; 4: 794-801.
- Rastogi L. Kora AJ, Arunachalam J. Highly stable, protein capped gold nanoparticles as effective drug delivery vehicles for amino glycosides antibiotics. Materials Science and Engineering C. 2012; 32: 1571-77.
- Rai A, Prabhune A, Perry CC. Antibiotic mediated synthesis of gold nanoparticles with potent antimicrobial activity and their application in antimicrobial coatings. J Mater Chem. 2010; 20: 6789-98.
- Tom RJ, Suryanarayanan V, Reddy PG, Baskaran S, Pradeep T. Ciprofloxacin protected gold nanoparticles. Langmuir. 2004; 20: 1909-14.
- Loechler, E.L., King, J., 1986. Identification of the 9-aminoacridine/DNA complex responsible for photodynamic inactivation of P22. Biochemistry. 25, 5858–5864.
- Zhu, H., Clark, S.M., Benson, S.C., Rye, A.N., Mathies, A.N., 1994. High-sensitivity capillary electrophoresis of double-stranded DNA fragments using monomeric and dimeric fluorescent intercalating. Dyes Anal. Chem. 66, 1941–1948.
- Mitra P, Chakraborty PK, Saha P, Ray P, Basu S. Antibacterial efficacy of acridine derivatives conjugated with gold nanoparticles. Int J Pharm. 2014; 473: 636-43.
- Gu H, Ho PL, Tong E, Wang L, Xu B. Presenting vancomycin on nanoparticles to enhance antimicrobial activities. Nano Letters. 2003; 3 (9): 1261-63.
- Huang WC, Tsai PJ, Chen YC. Functional gold nanoparticles as photothermal agents for selective-killing of pathogenic bacteria. Nanomedicine. 2007; 2 (6): 777-87.
- Tomas JG, Tubby S, Parkin IP, Narband N, Dekker L, Nair SP, Wilson M, Street C. Lethal photosensitisation of Staphylococcus aureus using a toluidine blueO-tiopronin–gold nanoparticle conjugate. J Mater Chem. 2007; 17: 3739-46.
- Zhao Y, Tian Y, Cui Y, Liu W, Ma W, Jiang X. Small molecule-capped gold nanoparticles as potent antibacterial agents that target gram-negative bacteria. J Am Chem Soc. 2010; 132 (35): 1234956.
- Zhao Y, Chen Z, Chen Y, Xu J, Li J, Jiang X. Synergy of nonantibiotic drugs and pyrimidinethiol on gold nanoparticles against superbugs. J Am Chem Soc. 2013; 135 (35): 12940-43.
- Bowman MC, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C. Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc. 2008;130(22):6896-97.
- Gomes A, Datta P, Sengupta J, Biswas A, Gomes A. Evaluation of anti-arthritic property of methotrexate conjugated gold nanoparticle on experimental animal models. J Nanopharmaceutics Drug Delivery. 2013; 1 (1): 1-6.
- Recent Updates on Psoriasis: A Review
Authors
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
2 Department of Pharmaceutical Analysis and Quality Assurance, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
Source
Asian Journal of Pharmaceutical Research, Vol 12, No 1 (2022), Pagination: 76 - 83Abstract
In the past 15 years, breakthroughs in the understanding towards the pathogenesis of psoriasis have been translated into highly and targeted effective therapies which provides fundamental insights into the pathogenesis of chronic inflammatory diseases. In this article we understand the mechanisms involved in the initiation and development of psoriasis, as well as the therapeutic options that arises from the dissection of the inflammatory psoriatic pathways. The whole discussion begins by addressing the inflammatory pathways and key cell types which initiating and perpetuating the psoriatic inflammation. Also, we discuss the role of genetics, associated epigenetic mechanisms, and the interaction of the skin flora in the pathophysiology of psoriasis. So, we the purpose of our study is to understand psoriasis comprehensively, and this review is well-established to explain the therapies, and other novel targeted drugs that are mostly used in the effective treatment of psoriasis.
Keywords
Psoriasis, Types, Pathogenesis, Epidemiology, PharmacotherapyReferences
- Mabuchi T, Chang TW, Quinter S and Hwang ST. Chemokine receptors in the pathogenesis and therapy of psoriasis. Journal of Dermatological Science. 2012;65(1): 4-11
- Tsuruta D. NF-κB links keratinocytes and lymphocytes in the pathogenesis of psoriasis. Recent Patents on Inflammation and Allergy Drug Discovery. 2009; 3(1): 40-8.
- Krueger JG and Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Annals of the Rheumatic Diseases 2005; 64(2): 30-6.
- Sondhi S, Singh N, Jindal S. Natural Remedies used in the Treatment of Psoriasis: A short Review. Asian Journal of Pharmaceutical Research. 2021;11(1):43-5.
- Nograles KE and Krueger JG. Anti-cytokine therapies for psoriasis. Experimental Cell Research. 2011; 317(9): 1293-300.
- Galimova ES, Akhmetova VL and Khusnutdinova EK. Molecular genetic basis of susceptibility to psoriasis. Russian Journal of Genetics. 2008; 44(5): 513.
- Campalani E and Barker JN. The clinical genetics of psoriasis. Current Genomics. 2005; 6(1): 51-60.
- A Kumar, S Jindal, MS Ashawat, V Pandit, V Priya. Psoriasis and Its Treatment: A Review.
- Vani PB, Kumar PR. A Comparative Review on Conventional and Traditional medicine in the Treatment of Psoriasis. Research Journal of Pharmacy and Technology. 2020;13(11):5642-6.
- Lebwohl M, Menter A, Koo J and Feldman SR. Combination therapy to treat moderate to severe psoriasis. Journal of the American Academy of Dermatology. 2004; 50(3): 416-30.
- Armstrong AW, Schupp C, Wu J and Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PloS one. 2012; 7(12): e52935.
- Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A and Turner ML. Quantifying the harmful effect of psoriasis on health-related quality of life. Journal of the American Academy of Dermatology 2002; 47(4): 512-8.
- Kimball AB, Gieler U, Linder D, Sampogna F and Warren RB: 33. Psoriasis: is the impairment to a patient’s life cumulative? Journal of the European Academy of Dermatology and Venereology. 2010; 24(9): 989-04. 34.
- Azfar RS, Seminara NM, Shin DB, Troxel AB and Margolis DJ. Increased risk of diabetes mellitus and the likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Archives of Dermatology. 2012; 148(9): 995-00. 35.
- Iriventi P, Gupta NV. Formulation and Evaluation of herbal cream for treating psoriasis. Research Journal of Pharmacy and Technology. 2021;14(1):167-70.
- Gisondi P and Girolomoni G. Cardiometabolic comorbidities and the approach to patients with psoriasis. Actas Dermo- Sifiliograficas. 2009; 100: 14-21.
- Paller AS, Mercy K, Kwasny MJ, Choon SE and Cordoro KM. 37. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatology. 2013; 149(2): 166-76.
- Parisi R, Symmons DP, Griffiths CE and Ashcroft DM. Global 38. epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013; 133: 377- 85. 286-92.
- Pradhan M, Alexander A. Development and Validation of a 39. Robust RP-HPLC Method for Analysis of Calcipotriol in Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology. 2019;12(2):579-83.
- Bedi TR. Clinical profile of psoriasis in North India. Indian Journal of Dermatology, Venereology and Leprology. 1995; 61(4): 202.
- Kaur I, Handa S and Kumar B. Natural history of psoriasis: a study from the Indian subcontinent. The Journal of Dermatology. 1997; 24(4): 230-4.
- Gillard SE and Finlay AY. Current management of psoriasis in the United Kingdom: patterns of prescribing and resource use in primary care. International Journal of Clinical Practice. 2005; 59(11): 1260-7.
- Rawat Singh M, Pradhan K and Singh D. Lipid matrix systems with emphasis on lipid microspheres: potent carriers for transcutaneous delivery of bioactives. Current Drug Delivery. 2012; 9(3): 243-54.
- Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. Journal of Controlled Release. 2001; 73(2- 3): 137-72.
- Kaplan FO, Daniel H and Barker J: Mechanisms of Disease: Psoriasis. Nestle In: New England Journal of Medicine. 2009; 361(5): 496-09.
- Christophers E, Segaert S, Milligan G, Molta CT and Boggs R: Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross- sectional observational study. Journal of Dermatological Treatment. 2013; 24(3): 193-8.
- Chaurasia V, Pal S. Skin diseases prediction: binary classification machine learning and multi model ensemble techniques. Research Journal of Pharmacy and Technology. 2019;12(8):3829-32.
- Pietrzak AT, Zalewska A, Chodorowska G, Krasowska D and Michalak-Stoma A. Cytokines and anticytokines in psoriasis. Clinica Chimica Acta. 2008; 394(1-2): 7-21.
- Raychaudhuri SP and Gross J: A comparative study of pediatric- onset psoriasis with adult-onset psoriasis. Pediatric Dermatology. 2000; 17(3): 174-8.
- Yadav K, Singh D, Singh MR. Development and characterization of corticosteroid loaded lipid carrier system for psoriasis. Research Journal of Pharmacy and Technology. 2021;14(2):966-70.
- D'souza JI, More HN. Topical anti-inflammatory gels of fluocinolone acetonide entrapped in eudragit based microsponge delivery system. Research Journal of Pharmacy and Technology. 2008; 1(4):502-6.
- Kavitha S. Pharmacognostical Evaluation and Standardisation of Ayurvedic Formulation Patoladi Kwatha Churna for Psoriasis. Research Journal of Pharmacy and Technology. 2020; 13(3): 1171-4.
- Wozel G: Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clinics in Dermatology. 2008; 26(5): 448- 59.
- Mahajan Tejasavi, Singh Navdeep, Goyal Kamya, Pandit Vinay, Ashawat M.S., Jindal Shammy. World dendrimer as a potential drug delivery system: a review. Journal of Pharmacy and Pharmaceutical Sciences. 2021; 10 (4): 1818-1827
- Jindal S, Awasthi R, Singare D, Kulkarni GT. Andrographolide loaded topical nanocarriers for management of psoriasis: a safe and effective approach. Plant Archives. 2021; 21(1):1899-902.
- Krishnamurthy K, Walker A, Gropper CA and Hoffman C. To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A Streptococcal infection. Journal of Drugs in Dermatology. 2010; 9(3): 241-50.
- Jindal S, Awasthi R, Singare D, Kulkarni GT. Preparation and in vitro evaluation of Tacrolimus loaded liposomal vesicles by two methods: A comparative study. Journal of Research in Pharmacy. 2021, 25(1): 34-41.
- Singh N, Sondhi S, Jindal S, Pandit V, Ashawat MS. Treatment and Management for patients with mild to severe Psoriasis: A Review. Asian Journal of Pharmaceutical Research. 2020; 10(4):286-92.
- Nandgude TD, Hasabe PS, Kolsure AK. Clinical Features and Treatment of Rheumatoid Arthritis: A Review. Research Journal of Pharmacy and Technology. 2018;11(12):5701-6.
- Kumar A, Goyal K, Pandit V , Ashawat MS, Jindal S. Simultaneous estimation of Halobetasol propionate and Tazarotene in pure and dosage form by using UV-Visible Spectrophotometric method. Research Journal of Pharmacy and Technology. 2020; 13(10): 4711-4.
- Jindal S, Awasthi R, Singhare D, Kulkarni GT. Topical delivery of Tacrolimus using liposome containing gel: An emerging and synergistic approach in management of psoriasis. Medical Hypotheses. 2020; 142:109838.
- Sondhi S, Singh N, Goyal K, Jindal S. A Laconic Review on Extraction, Biological Activities of Herbal Formulations of Berberine: A Traditional Drug. Journal of Drug Delivery and Therapeutics. 2020;10(5):345-57.
- Singh N, Goyal K, Sondhi S, Jindal S. Traditional and medicinal use of Barbaloin: potential for the management of various diseases. Journal of Applied Pharmaceutical Research. 2020; 8(3):21-30.
- Mrowietz U, Kragballe K, Reich K, Spuls P and Griffiths CE: Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research. 2011; 303(1): 1-0.
- Singh N, Goyal K, Sondhi S, Jindal S. Development and Characterization of Barbaloin Gel for the Safe and Effective Treatment of Psoriasis. Journal of Drug Delivery and Therapeutics. 2020; 10(5):188-97.
- Sondhi S, Singh N, Jindal S. Natural Remedies used in the Treatment of Psoriasis: A short Review. Asian Journal of Pharmaceutical Research. 2021;11(1):43-5.
- Sharma S, Sharma R, Goyal K, Jindal S. Potential of herbal treatment of Psoriasis: A Laconic Review. Asian Journal of Research in Pharmaceutical Sciences. 2021;11(1):51-7.
- Sondhi S, Singh N, Goyal K, Jindal S. Development of Topical Herbal Gel of Berberine Hydrochloride for the Treatment of Psoriasis. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021;13(1):12-8.
- Sharma A, Anghore D, Awasthi R, Kosey S, Jindal S, Gupta N, Raj D, Sood R. A Review on Current Carbon Nanomaterials and Other Nanoparticles Technology and Their Applications in Biomedicine. World Journal Pharmacy and Pharmaceutical Science. 2015;4(12):1088-113.
- Jindal S, Awasthi R, Singare D, Kulkarni GT. Isolation, characterization and evaluation of anti-proliferative properties of andrographolide isolated from Andrographis paniculata on cultured HaCaT cells. Herba Polonica. 2021; 67(1): 35-45.
- Application of Nanocarrier in Drug development with special Emphasis on Liposomes: A Review
Authors
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
2 Department of Pharmaceutical Analysis and Quality Assurance, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
Source
Asian Journal of Pharmacy and Technology, Vol 12, No 4 (2022), Pagination: 320-328Abstract
Liposomes are the nano-scale bilayer structure of phospholipid used as a carrier for a Large Variety of drugs. Both lipophilic and hydrophilic drugs can encapsulate into the liposome and delivered to the body. The purpose behind the preparation of liposomes is to reduce the side effects associated with systemic delivery of drugs as well as it also helps in the protection of biodegradable drugs and molecules such as protein and peptides from body enzymes and fluids. Other than these advantages liposome also have high skin permeation due to structural similarities with the stratum corneum and therefore can be used for the topical delivery of drugs. The various types of liposomes and their application in their marketed products are discussed below in the article.Keywords
Liposome, Gene Therapy, Theranostic ApplicationsReferences
- Gomez-Hens A, Fernández-Romero JM. The role of liposomes in analytical processes. TrAC Trends Anal Chem. 2005;24(1):9–19.
- Has C, Sunthar P. A comprehensive review on recent preparation techniques of liposomes. J Liposome Res. 2020;30(4):336–65.
- Manconi M, Caddeo C, Sinico C, Valenti D, Mostallino MC, Biggio G, et al. Ex vivo skin delivery of diclofenac by transcutol containing liposomes and suggested mechanism of vesicle–skin interaction. Eur J Pharm Biopharm. 2011;78(1):27–35.
- Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349.
- Akhtar N. Vesicles: a recently developed novel carrier for enhanced topical drug delivery. Curr Drug Deliv. 2014;11(1):87–97.
- Jindal S, Awasthi R, Singare D, Kulkarni GT. Preparation and in vitro evaluation of Tacrolimus loaded liposomal vesicles by two methods: A comparative study. J Res Pharm. 2021;25(1):34–41.
- Chowdhury A, Kunjiappan S, Panneerselvam T, Somasundaram B, Bhattacharjee C. Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases. Int nano Lett. 2017;7(2):91–122.
- Siddiqi KS, Husen A, Sohrab SS, Yassin MO. Recent status of nanomaterial fabrication and their potential applications in neurological disease management. Nanoscale Res Lett. 2018;13(1):1–17.
- Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193.
- Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H. Macromolecular therapeutics. Clin Pharmacokinet. 2003;42(13):1089–105.
- Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11(17–18):812–8.
- Nakamura H, Jun F, Maeda H. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin Drug Deliv. 2015;12(1):53–64.
- Çağdaş M, Sezer AD, Bucak S. Liposomes as potential drug carrier systems for drug delivery. Appl Nanotechnol drug Deliv. 2014;1:1–50.
- Ranade V V. Drug delivery systems. 1. Site‐specific drug delivery using liposomes as carriers. J Clin Pharmacol. 1989;29(8):685–94.
- Choudhury H, Gorain B, Pandey M, Chatterjee LA, Sengupta P, Das A, et al. Recent update on nanoemulgel as topical drug delivery system. J Pharm Sci. 2017;106(7):1736–51.
- Rahimpour Y, Hamishehkar H. Liposomes in cosmeceutics. Expert Opin Drug Deliv. 2012;9(4):443–55.
- Kaur IP, Kakkar S. Topical delivery of antifungal agents. Expert Opin Drug Deliv. 2010;7(11):1303–27.
- Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide vaccine: progress and challenges. Vaccines. 2014;2(3):515–36.
- Gregory AE, Williamson D, Titball R. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013;3:13.
- Tandrup Schmidt S, Foged C, Smith Korsholm K, Rades T, Christensen D. Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators. Pharmaceutics. 2016;8(1):7.
- Khalaj‐Hedayati A, Chua CLL, Smooker P, Lee KW. Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement. Influenza Other Respi Viruses. 2020;14(1):92–101.
- Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015;10(2):81–98.
- Singh RP, Gangadharappa H V, Mruthunjaya K. Phospholipids: Unique carriers for drug delivery systems. J Drug Deliv Sci Technol. 2017;39:166–79.
- Paltauf F, Hermetter A. Phospholipids—Natural, semisynthetic, synthetic. In: Phospholipids. Springer; 1990. p. 1–12.
- Ahmed KS, Hussein SA, Ali AH, Korma SA, Lipeng Q, Jinghua C. Liposome: Composition, characterisation, preparation, and recent innovation in clinical applications. J Drug Target. 2019;27(7):742–61.
- Silvius JR. Role of cholesterol in lipid raft formation: lessons from lipid model systems. Biochim Biophys Acta (BBA)-Biomembranes. 2003;1610(2):174–83.
- Harayama T, Riezman H. Understanding the diversity of membrane lipid composition. Nat Rev Mol cell Biol. 2018;19(5):281–96.
- Zhukovsky MA, Filograna A, Luini A, Corda D, Valente C. Phosphatidic acid in membrane rearrangements. FEBS Lett. 2019;593(17):2428–51.
- Iscaro A, Howard NF, Muthana M. Nanoparticles: properties and applications in cancer immunotherapy. Curr Pharm Des. 2019;25(17):1962–79.
- P Samy R, Gopalakrishnakone P, G Stiles B, S Girish K, N Swamy S, Hemshekhar M, et al. Snake venom phospholipases A2: a novel tool against bacterial diseases. Curr Med Chem. 2012;19(36):6150–62.
- Jindal S, Awasthi R, Singhare D, Kulkarni GT. Topical delivery of Tacrolimus using liposome containing gel: An emerging and synergistic approach in management of psoriasis. Med Hypotheses. 2020;142:109838.
- Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des. 2004;10(24):2981–9.
- Panahi Y, Farshbaf M, Mohammadhosseini M, Mirahadi M, Khalilov R, Saghfi S, et al. Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications. Artif cells, nanomedicine, Biotechnol. 2017;45(4):788–99.
- Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif cells, nanomedicine, Biotechnol. 2016;44(1):381–91.
- Jindal S, Kumar A, Goyal K, Awasthi R, Kulkarni GT. Lipid Nanocarriers for Dermal Delivery of Lutein. In: Nanomedicine for Bioactives. Springer; 2020. p. 341–66.
- Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003.
- Huang Z, Li X, Zhang T, Song Y, She Z, Li J, et al. Progress involving new techniques for liposome preparation. asian J Pharm Sci. 2014;9(4):176–82.
- Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett. 2005;10(4):711.
- Paternostre MT, Roux M, Rigaud JL. Mechanisms of membrane protein insertion into liposomes during reconstitution procedures involving the use of detergents. 1. Solubilization of large unilamellar liposomes (prepared by reverse-phase evaporation) by triton X-100, octyl glucoside, and sodium. Biochemistry. 1988;27(8):2668–77.
- Edwards K, Johnsson M, Karlsson G, Silvander M. Effect of polyethyleneglycol-phospholipids on aggregate structure in preparations of small unilamellar liposomes. Biophys J. 1997;73(1):258–66.
- Kumar S, Kaur N, Mithu VS. Amphiphilic ionic liquid induced fusion of phospholipid liposomes. Phys Chem Chem Phys. 2020;22(43):25255–63.
- Zhang H. Thin-film hydration followed by extrusion method for liposome preparation. In: Liposomes. Springer; 2017. p. 17–22.
- Fernández-García R, Lalatsa A, Statts L, Bolás-Fernández F, Ballesteros MP, Serrano DR. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale. Int J Pharm. 2020;573:118817.
- Varona S, Martin A, Cocero MJ. Liposomal incorporation of lavandin essential oil by a thin-film hydration method and by particles from gas-saturated solutions. Ind Eng Chem Res. 2011;50(4):2088–97.
- Marsden HR, Gabrielli L, Kros A. Rapid preparation of polymersomes by a water addition/solvent evaporation method. Polym Chem. 2010;1(9):1512–8.
- Zhang X, Coleman AC, Katsonis N, Browne WR, Van Wees BJ, Feringa BL. Dispersion of graphene in ethanol using a simple solvent exchange method. Chem Commun. 2010;46(40):7539–41.
- Kim SW, Kim T, Kim YS, Choi HS, Lim HJ, Yang SJ, et al. Surface modifications for the effective dispersion of carbon nanotubes in solvents and polymers. Carbon N Y. 2012;50(1):3–33.
- Ming-Jie LI, ZHANG H-Y, Xiao-Zhe LIU, Chun-Yan CUI, Zhi-Hong SHI. Progress of extraction solvent dispersion strategies for dispersive liquid-liquid microextraction. Chinese J Anal Chem. 2015;43(8):1231–40.
- Chen J, Brooks III CL, Khandogin J. Recent advances in implicit solvent-based methods for biomolecular simulations. Curr Opin Struct Biol. 2008;18(2):140–8.
- Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci. 1978;75(9):4194–8.
- Mertins O, Sebben M, Pohlmann AR, da Silveira NP. Production of soybean phosphatidylcholine–chitosan nanovesicles by reverse phase evaporation: a step by step study. Chem Phys Lipids. 2005;138(1–2):29–37.
- Taylor KMG, Taylor G, Kellaway IW, Stevens J. Drug entrapment and release from multilamellar and reverse-phase evaporation liposomes. Int J Pharm. 1990;58(1):49–55.
- Trucillo P, Campardelli R, Reverchon E. Liposomes: From bangham to supercritical fluids. Processes. 2020;8(9):1022.
- Jung J, Perrut M. Particle design using supercritical fluids: literature and patent survey. J Supercrit Fluids. 2001;20(3):179–219.
- Naik S, Patel D, Surti N, Misra A. Preparation of PEGylated liposomes of docetaxel using supercritical fluid technology. J Supercrit Fluids. 2010;54(1):110–9.
- Xia F, Hu D, Jin H, Zhao Y, Liang J. Preparation of lutein proliposomes by supercritical anti-solvent technique. Food Hydrocoll. 2012;26(2):456–63.
- Booysen E. Characterization of a novel antibiotic isolated from Xenorhabdus khoisanae and encapsulation of vancomycin in nanoparticles. Stellenbosch: Stellenbosch University; 2018.
- Lesoin L, Crampon C, Boutin O, Badens E. Preparation of liposomes using the supercritical anti-solvent (SAS) process and comparison with a conventional method. J Supercrit Fluids. 2011;57(2):162–74.
- Kompella UB, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Crit Rev Ther Drug Carr Syst. 2001;18(2).
- Amoabediny G, Haghiralsadat F, Naderinezhad S, Helder MN, Akhoundi Kharanaghi E, Mohammadnejad Arough J, et al. Overview of preparation methods of polymeric and lipid-based (niosome, solid lipid, liposome) nanoparticles: A comprehensive review. Int J Polym Mater Polym Biomater. 2018;67(6):383–400.
- van Swaay D, DeMello A. Microfluidic methods for forming liposomes. Lab Chip. 2013;13(5):752–67.
- Yu B, Lee RJ, Lee LJ. Microfluidic methods for production of liposomes. Methods Enzymol. 2009;465:129–41.
- Amrani S. Microfluidic platform for the fabrication and loading of nanoscale liposomes by 2D hydrodynamic flow focusing. McGill University (Canada); 2018.
- Cheung C. Preparation of Multifunctional Nanoparticles Using Microfluidics. Queen’s University Belfast; 2020.
- Shum HC, Thiele J, Kim S-H. Microfluidic fabrication of vesicles. Adv Transp Phenom 2011. 2014;1–28.
- Hu PC, Li S, Malmstadt N. Microfluidic fabrication of asymmetric giant lipid vesicles. ACS Appl Mater Interfaces. 2011;3(5):1434–40.
- Vayssieres L, Keis K, Hagfeldt A, Lindquist S-E. Three-dimensional array of highly oriented crystalline ZnO microtubes. Chem Mater. 2001;13(12):4395–8.
- Ding X, Zeng D, Zhang S, Xie C. C-doped WO3 microtubes assembled by nanoparticles with ultrahigh sensitivity to toluene at low operating temperature. Sensors Actuators B Chem. 2011;155(1):86–92.
- Li Q, Wang X, Ma S, Zhang Y, Han X. Electroformation of giant unilamellar vesicles in saline solution. Colloids Surfaces B Biointerfaces. 2016;147:368–75.
- Stein H, Spindler S, Bonakdar N, Wang C, Sandoghdar V. Production of isolated giant unilamellar vesicles under high salt concentrations. Front Physiol. 2017;8:63.
- Kuribayashi K, Tresset G, Coquet P, Fujita H, Takeuchi S. Electroformation of giant liposomes in microfluidic channels. Meas Sci Technol. 2006;17(12):3121.
- Kanha N, Regenstein JM, Surawang S, Pitchakarn P, Laokuldilok T. Properties and kinetics of the in vitro release of anthocyanin-rich microcapsules produced through spray and freeze-drying complex coacervated double emulsions. Food Chem. 2021;340:127950.
- Kim TH, Park TG. Critical effect of freezing/freeze-drying on sustained release of FITC-dextran encapsulated within PLGA microspheres. Int J Pharm. 2004;271(1–2):207–14.
- Supramaniam P, Ces O, Salehi-Reyhani A. Microfluidics for artificial life: techniques for bottom-up synthetic biology. Micromachines. 2019;10(5):299.
- Monteiro N, Martins A, Reis RL, Neves NM. Liposomes in tissue engineering and regenerative medicine. J R Soc Interface. 2014;11(101):20140459.
- Xue J, Wu T, Dai Y, Xia Y. Electrospinning and electrospun nanofibers: Methods, materials, and applications. Chem Rev. 2019;119(8):5298–415.
- Mohanraj VJ, Chen Y. Nanoparticles-a review. Trop J Pharm Res. 2006;5(1):561–73.
- Jadhav SM, Morey P, Karpe M, Kadam V. Novel vesicular system: an overview. J Appl Pharm Sci. 2012;2(1):193–202.
- Narvekar M, Xue HY, Eoh JY, Wong HL. Nanocarrier for poorly water-soluble anticancer drugs—barriers of translation and solutions. Aaps Pharmscitech. 2014;15(4):822–33.
- Alam A, Farooq U, Singh R, Dubey VP, Kumar S, Kumari R, et al. Chemotherapy treatment and strategy schemes: A review. Open Access J Toxicol. 2018;2(5):555600.
- Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.
- Overchuk M, Zheng G. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics. Biomaterials. 2018;156:217–37.
- Lila ASA, Ishida T. Liposomal delivery systems: design optimization and current applications. Biol Pharm Bull. 2017;40(1):1–10.
- Sharma G, Anabousi S, Ehrhardt C, Ravi Kumar MN V. Liposomes as targeted drug delivery systems in the treatment of breast cancer. J Drug Target. 2006;14(5):301–10.
- Singh N, Sondhi S, Sharma S, Singh D, Koundal V, Goyal K, et al. Treatment of Skin Cancer by Topical Drug Delivery of Nanoparticles: A Review. Res J Pharm Technol. 2021;14(10):5589–98.
- Tamura A, Nagasaki Y. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. Nanomedicine. 2010;5(7):1089–102.
- Mohammadinejad R, Dehshahri A, Madamsetty VS, Zahmatkeshan M, Tavakol S, Makvandi P, et al. In vivo gene delivery mediated by non-viral vectors for cancer therapy. J Control Release. 2020;325:249–75.
- Jindal S, Awasthi R, Singare D, Kulkarni GT. POTENTIAL OF HERBAL NANOCARRIER FORMULATION FOR THE TREATMENT OF PSORIASIS. Int J Pharm Life Sci. 2019;10(6).
- Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed. 2007;18(3):241–68.
- Zhou J, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides. 2011;21(1):1–10.
- Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. 2008;
- Frezard F. Liposomes: from biophysics to the design of peptide vaccines. Brazilian J Med Biol Res. 1999;32(2).
- Nam G, Choi Y, Kim GB, Kim S, Kim SA, Kim I. Emerging prospects of exosomes for cancer treatment: from conventional therapy to immunotherapy. Adv Mater. 2020;32(51):2002440.
- Madni A, Sarfraz M, Rehman M, Ahmad M, Akhtar N, Ahmad S, et al. Liposomal drug delivery: a versatile platform for challenging clinical applications. J Pharm Pharm Sci. 2014;17(3):401–26.
- García A, De Sanctis JB. An overview of adjuvant formulations and delivery systems. Apmis. 2014;122(4):257–67.
- Du Y-F, Chen M, Xu J-R, Luo Q, Lu W-L. Preparation and Characterization of DNA Liposomes Vaccine. Liposome-Based Drug Deliv Syst. 2021;259–75.
- Sharma A, Anghore D, Awasthi R, Kosey S, Jindal S, Gupta N, et al. A review on current carbon nanomaterials and other nanoparticles technology and their applications in biomedicine. World J Pharm Pharm Sci. 2015;4(12):1088–113.
- Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975.
- Gowda GAN, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn. 2008;8(5):617–33.
- Papanicolaou GN, Traut HF. Diagnosis of uterine cancer by the vaginal smear. New York. 1943;46.
- Mulder WJM, Strijkers GJ, Griffioen AW, van Bloois L, Molema G, Storm G, et al. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem. 2004;15(4):799–806.
- Mukundan Jr S. Ghaghada KB, Badea CT, Kao CY, Hedlund LW, Provenzale JM, Johnson GA, Chen E, Bellamkonda RV, Annapragada A. A liposomal nanoscale contrast agent for preclinical CT in mice. AJR Am J Roentgenol. 2006;186(2):300–7.
- Costabile RA, Choyke PL, Frank JA, Girton ME, Diggs R, Billups KL, et al. Dynamic enhanced magnetic resonance imaging of testicular perfusion in the rat. J Urol. 1993;149(5):1195–7.
- Patravale VB, Mandawgade SD. Novel cosmetic delivery systems: an application update. Int J Cosmet Sci. 2008;30(1):19–33.
- Budai L, Kaszás N, Gróf P, Lenti K, Maghami K, Antal I, et al. Liposomes for topical use: A physico-chemical comparison of vesicles prepared from egg or soy lecithin. Sci Pharm. 2013;81(4):1151–66.
- Al-Jamal W, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res. 2011;44(10):1094–104.
- Svenson S. Theranostics: are we there yet? Mol Pharm. 2013;10(3):848–56.
- Mukherjee A, Paul M, Mukherjee S. Recent progress in the theranostics application of nanomedicine in lung cancer. Cancers (Basel). 2019;11(5):597.
- Yin W, Kimbrough CW, Gomez-Gutierrez JG, Burns CT, Chuong P, Grizzle WE, et al. Tumor specific liposomes improve detection of pancreatic adenocarcinoma in vivo using optoacoustic tomography. J Nanobiotechnology. 2015;13(1):1–11.
- Gurka MK, Pender D, Chuong P, Fouts BL, Sobelov A, McNally MW, et al. Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography. J Control release. 2016;231:60–7.
- Wallace TL, Larson JL, Bazemore SA, Wilson CW, Cossum PA. The nonclinical safety evaluation of the anticancer drug ATRAGEN®(Liposomal all-trans-retinoic acid). Int J Toxicol. 2000;19(1):33–42.
- Brogden RN, Goa KL, Coukell AJ. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis. Drugs. 1998 Sep;56(3):365–83.
- Sharma M, Joshi J, Chouhan NK, Talati MN, Vaidya S, Kumar A. Liposome-A Comprehensive Approach for Researchers. In: Molecular Pharmacology. IntechOpen; 2020.
- Chhikara BS, Parang K. Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opin Drug Deliv. 2010;7(12):1399–414.
- Porche DJ. Liposomal doxorubicin (Doxil). J Assoc Nurses AIDS Care. 1996;7(2):55–9.
- Wang R, Billone PS, Mullett WM. Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J Nanomater. 2013;2013.
- Peravali R, Brock R, Bright E, Mills P, Petty D, Alberts J. Enhancing the Enhanced Recovery Program in Colorectal Surgery-use of extended-release epidural morphine (DepoDur®). Ann Coloproctol. 2014;30(4):186.
- Estradiol-topical--Novavax: Estrasorb. Drugs R D. 2003;4(1):49–51.
- Lea AP, Balfour JA. Virosomal hepatitis A vaccine (strain RG-SB). BioDrugs. 1997;7(3):232–48.
- Xiong Y-Q, Kupferwasser LI, Zack PM, Bayer AS. Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses. Antimicrob Agents Chemother. 1999;43(7):1737–42.
- Dhandapani NV, Thapa A, Sandip G, Shrestha A, Shrestha N, Bhattarai RS. Liposomes as novel drug delivery system: A comprehensive review. 2013;
- Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442–53.
- Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother. 1998;42(6):1412–6.
- Passero Jr FC, Grapsa D, Syrigos KN, Saif MW. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert Rev Anticancer Ther. 2016;16(7):697–703.
- Rheumatoid Arthritis, a Laconic Review to Understand Their Basic Concept and Management Process
Authors
1 Research Scholar, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
2 Assistant Professor, Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
3 Head of Department, Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
4 Director cum Principal, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh 176031, IN
5 Assistant Professor, Laureate Institute of Pharmacy, Jawalmukhi - 176031, Himachal Pradesh, IN
Source
Asian Journal of Pharmaceutical Research, Vol 12, No 4 (2022), Pagination: 312 - 322Abstract
Rheumatoid arthritis is a chronic inflammatory illness characterized by joint stiffness, bone and cartilage destruction, and swelling above the joints. The condition is linked to chemicals found within the major histocompatibility complex, also as T-cells that are hooked in to them. The condition is more severe in women than in men, also as within the elderly population. The effects of gender on the clinical course of the disease are studied, but the results are mixed. The factor like genetic, environmental, smoking, and age of a person were trigger’s the rheumatoid arthritis. The other clinical complications were observed in patients with rheumatoid arthritis which includes depression, infection, malignancy, cardiovascular disorder, pulmonary disease etc. According to research, RA risk might be impacted by a genetic predisposition, environmental factors, or a combination of both. Immune cells such as lymphocytes, neutrophils, and macrophages have long been thought to have a role in the development of RA involved in pathological mechanism. Rheumatoid arthritis have been diagnosed by imaging with colour doppler sonography or gadolinium-enhanced magnetic resonance imaging can detect the presence of osynovitis, and serologic testing for auto-antibodies and APRs was required to diagnose rheumatoid arthritis. To cure and prevent the patients form rheumatoid arthritis it is very necessary to take suitable treatment. So, in present work we also highlighted the available drugs used for the treatment of RA. The first line therapy agents include Non-steroidalantiinflammatory drugs, and corticosteroids. The second line agents used in RA are Disease modifying Antirheumatic drugs (DMARDs). The patients having age more than 60 years also need surgery to cure rheumatoid arthritis. To decrease the side effects from some potent agents include methotrexate the vitamin D, folic acid, and dietary supplements were used with treatment. So, this review article helps the researcher’s to understand the basic overview of rheumatoid arthritis, causes, other disease development, and management process with regards to available FDA approved therapeutics, and published patents.
Keywords
Rheumatoid arthritis, Etiology, Pathophysiology, Diagnosis, TreatmentReferences
- Aloke C, Ibiam UA, Orji OU, Ugwuja EI, Ezeani NN, Aja PM, Obasi NA. Anti-arthritic potentials of ethanol and aqueous extracts of stem bark of Cleistopholis patens on complete Freund's adjuvant-induced rheumatoid arthritis in rats. Journal of Ayurveda and Integrative Medicine. 2019:9.
- 2. Girdler SJ, Ye I, Tang R, Kirschner N. Altering the natural history of rheumatoid arthritis: The role of Immunotherapy and biologics in orthopaedic care. Journal of Orthopaedics. 2020; 17:17-21.
- Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF. Thoracic manifestations of rheumatoid arthritis. Clinics in Chest Medicine. 2019;40(3):545-60.
- Jayashree S, Nirekshana K, Guha G, Bhakta-Guha D. Cancer chemotherapeutics in rheumatoid arthritis: A convoluted connection. Biomedicine and Pharmacotherapy. 2018; 102:894-911.
- Arjun Patidar, S.C.Shivhare, Umesh Ateneriya, Sonu Choudhary. A Comprehensive Review on Breast Cancer. Asian J. Nur. Edu. and Research 2(1): Jan.-March 2012; Page 28-32.
- Tanaka S. Emerging anti-osteoclast therapy for rheumatoid arthritis. Journal of Orthopaedic Science. 2018;23(5):717-21.
- Wang X, Fang G, Yang Y, Pang Y. The newly discovered natural compounds against rheumatoid arthritis-an overview. Phytochemistry Letters. 2019; 34:50-8.
- Rekha Rani Nar, Ashok Kumar, S. Jeeva. Assessment and comparison of knowledge and attitude regarding pulmonary tuberculosis and compliance to Anti-Tuberculosis Treatment (A TT) of pulmonary tuberculosis patients under intensive and continuation phase of treatment at selected DOTS centers of Ambala, Haryana. Asian J. Nur. Edu. and Research 2(4): Oct-Dec. 2012; Page 190-194.
- Martins P, Fonseca JE. How to investigate: Pre-clinical rheumatoid arthritis. Best Practice and Research Clinical Rheumatology. 2019;33(4):101438.
- Alpízar-Rodríguez D, Pluchino N, Canny G, Gabay C, Finckh A. The role of female hormonal factors in the development of rheumatoid arthritis. Rheumatology. 2017;56(8):1254-63.
- Ramachandra. Hypochondria - Historical Perspectives, Diagnosis and Management. Asian J. Nur. Edu. and Research 3(4): Oct.- Dec., 2013; Page 219-223.
- ChangK,YangSM,KimSH,HanKH,ParkSJ,ShinJI.Smokingand rheumatoid arthritis. International Journal of Molecular Sciences. 2014;15(12):22279-95.
- Margaretten M, Julian L, Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. International Journal of Clinical Rheumatology. 2011;6(6):617.
- Atzeni F, Masala IF, Di Franco M, Sarzi-Puttini P. Infections in rheumatoid arthritis. Current Opinion in Rheumatology. 2017;29(4):323-30.
- Neethu Jose. Bee Venom Therapy (BVT). Asian J. Nur. Edu. and Research 5(2): April-June 2015; Page 293-296.
- Ellman P, Ball RE. “Rheumatoid disease” with joint and pulmonary manifestations. British Medical Journal. 1948;2(4583):816.
- Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF. Thoracic manifestations of rheumatoid arthritis. Clinics in Chest Medicine. 2019;40(3):545-60.
- Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology. 2014;53(12):2143-54.
- Nirmala Jyothi. A Case Report on Pica: A rare pregnancy related complication. Asian J. Nur. Edu. and Research 5(1): Jan.-March 2015; Page137-139.
- Wegierska M, Dura M, Blumfield E, Żuchowski P, Waszczak M, Jeka S. Osteoporosis diagnostics in patients with rheumatoid arthritis. Reumatologia. 2016;54(1):29.
- Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology. 2006;45(6):669-75.
- Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 2012;51(suppl_5): v3-11.
- Byng-Maddick R, Ehrenstein MR. The impact of biological therapy on regulatory T cells in rheumatoid arthritis. Rheumatology. 2015;54(5):768-75.
- Jophin Joseph. Pierre Robin Sequence / Pierre Robin malformation. Asian J. Nur. Edu. and Research. 2016; 6(2): 265-273.
- Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology. 2005;12(3):183-9.
- Bugatti S, Vitolo B, Caporali R, Montecucco C, Manzo A. B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. BioMed Research International. 2014.
- Kekow J, Koczan D, Drynda S, Drynda A, Thiesen H. Modulation of the gene expression pattern in peripheral blood mononuclear cells by biologicals in rheumatoid arthritis. Arthritis Res Ther. 2003;5(3):1-54.
- Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. Journal of Autoimmunity. 2012;39(3):222-8.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B. American College of Rheumatology, European League Against Rheumatism, et al: Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62:2569-81.
- Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Annals of the Rheumatic Diseases. 2014;73(1):114-23.
- Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, Brunner HI, Ogawa R, Felson D, Ogdie A, Aletaha D. Distinctions between diagnostic and classification criteria?. Arthritis Care and Research. 2015;67(7):891.
- Mohd. Yaqub Khan, Poonam Gupta, Vikas Kumar Verma. A Review- Biomedical Engineering-Present and Future Prospective.Asian J. Pharm. Res. 3(4): Oct. - Dec.2013; Page 202-206.
- Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Annals of the Rheumatic Diseases. 2002;61(4):290-7.
- Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Research and Therapy. 2005;7(4):1-1.
- Van der Heijde DM, van Riel PL, van Leeuwen MA. vant Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. Br J Rheumatol. 1992; 8:519-26.
- St Clair EW. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: randomized, controlled trial. Arthritis Rheum. 2004; 50:3432-43.
- Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases. 2016;75(1):3-15.
- Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Annals of the Rheumatic Diseases. 2012;71(10):1702-5.
- Felson DT, Smolen JS, Wells G, Zhang B, Van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism. 2011;63(3):573-86.
- Bullock J, Rizvi SA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice. 2018;27(6):501-7.
- Krushna K. Zambare, Avinash B. Thalkari. Overview on Pathophysiology of Pneumonia. Asian J. Pharm. Res. 2019; 9(3):177-180.
- Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R. 2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases. 2017;76(6):948-59.
- Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma and Clinical Immunology. 2013;9(1):1-25.
- Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases. 2010;69(6):964-75.
- Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R. 2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases. 2017;76(6):948-59.
- Silva JC, Mariz HA, Rocha LF, Oliveira PS, Dantas AT, Duarte AL, Pitta ID, Galdino SL, Pitta MG. Hydroxychloroquine decreases Th17- related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics. 2013; 68:766-71.
- Volin MV, Harlow LA, Woods JM, Campbell PL, Amin MA, Tokuhira M, Koch AE. Treatment with sulfasalazine or sulfapyridine, but not 5‐aminosalicylic acid, inhibits basic fibroblast growth factor–induced endothelial cell chemotaxis. Arthritis and Rheumatism: Official Journal of the American College of Rheumatology. 1999;42(9):1927-35.
- Kanchan R Pagar, Sarika V Khandbahale, Poonam M Kasar. Osteoarthritis: Pathophysiology and Current Treatment Modalities. Asian J. Pharm. Res. 2019; 9(4):289-298.
- Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2013;6: CMAMD-S5558.
- Bullock J, Rizvi SA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice. 2018;27(6):501-7.
- Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatology and Therapy. 2017;4(2):247-61.
- Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Therapeutic Advances in Drug Safety. 2011;2(3):113-28.
- Halstead JA, Stoten S. Orthopedic Nursing: Caring for Patients with Musculoskeletal Disorders. Bridgewater: Western Schools. 2010.
- Kanchan R Pagar, Sarika V Khandbahale, Poonam M Kasar. Osteoarthritis: Pathophysiology and Current Treatment Modalities. Asian J. Pharm. Res. 2019; 9(4):289-298.
- Bullock J, Rizvi SA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice. 2018;27(6):501-7.
- Cooney JK, Law RJ, Matschke V, Lemmey AB, Moore JP, Ahmad Y, Jones JG, Maddison P, Thom JM. Benefits of exercise in rheumatoid arthritis. Journal of Aging Research.13;2011
- Zitnay JL, Li Y, Qin Z, San BH, Depalle B, Reese SP, Buehler MJ, Yu SM, Weiss JA. Molecular level detection and localization of mechanical damage in collagen enabled by collagen hybridizing peptides. Nature Communications. 2017;8(1):1-2.
- Burska AN, Roget K, Blits M, Gomez LS, Van De Loo F, Hazelwood LD, Verweij CL, Rowe A, Goulielmos GN, Van Baarsen LG, Ponchel F. Gene expression analysis in RA: towards personalized medicine. The Pharmacogenomics Journal. 2014;14(2):93-106.
- Nakamura S, Suzuki K, Iijima H, Hata Y, Lim CR, Ishizawa Y, Kameda H, Amano K, Matsubara K, Matoba R, Takeuchi T. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. Arthritis Research and Therapy. 2016;18(1):1-2.
- Gonzalez-Alvaro I, Ortiz AM, Seoane IV, Garcia-Vicuna R, Martínez C, Gomáriz RP. Biomarkers predicting a need for intensive treatment in patients with early arthritis. Current Pharmaceutical Design. 2015;21(2):170-81.
- Feldman M, Maini RN, Williams RO, inventors; Kennedy Mathilda, Terence Institute of Rheumatology Trust, assignee. Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti- TNF antibodies. United States Patent US 5,741,488. 1998 Apr 21.
- Dennis G, Martin F, Townsend MJ, inventors; Genentech Inc, assignee. Methods for treating, diagnosing, and monitoring rheumatoid arthritis. United States Patent US 8,728,730. 2014 May 20.
- Cavet GL, Shen Y, Knowlton N, Centola M, inventors; Oklahoma Medical Research Foundation, Crescendo Bioscience Inc, assignee. Biomarkers and methods for measuring and monitoring inflammatory disease activity. United States Patent US 9,200,324. 2015 Dec 1.
- Stolle RJ, Beck LR, inventors; Stolle Research, Development Corp, assignee. Prevention and treatment of rheumatoid arthritis. United States Patent US 4,732,757. 1988 Mar 22.
- Nithyashree RS, Deveswaran R. A Comprehensive Review on Rheumatoid Arthritis. Journal of Pharmaceutical Research International. 2020 Jul 27:18-32.
- Spencer WP, Millsap PS. Esterified fatty acid composition - IMAGENETIX, INC. Freepatentsonline.com; 2009. [Online] Available:http://www.freepatentsonline.com /y2009/0252692.html (Accessed 17 December 2019)
- Tetracycline Compounds for the Treatment of Rheumatoid Arthritis and Related Methods of Treatment - Patent US2010190755 - PubChem. Available:https://pubchem.ncbi.nlm.nih.gov /patent/US2010190755 (Accessed: 21 December 2019)
- Google.com. WO2015177097A1 - Treatment for rheumatoid arthritis - Google Patents; 2015. [Online] Available:https://patents.google.com/paten t/WO2015177097A1/en (Accessed 17 December 2019)
- Freepatentsonline.com. FPO IP Research and Communities; 2019. [Online] Available: http://www.freepatentsonline.com/result.html?sort=relevance&srch=to p&query_txt=5908628&submit=&patents_us=o n (Accessed 17 December 2019)
- Golini JM. Cetylated fatty acid and alkali buffered creatine anti- inflammatory composition –Golin, JeffreyM. Freepatentsonline.com; 2011. [Online] Available:http://www.freepatentsonline.co m/y2011/0039928.html (Accessed 17 December 2019)
- Cohen R, Belder-Carr S, Hagerty D, Peach RJ, Becker JC, inventors; Bristol Myers Squibb Co, assignee. Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule. United States patent US 8,703,718. 2014 Apr 22.
- Dennis G, Martin F, Townsend MJ, inventors; Genentech Inc, assignee. Methods for treating, diagnosing, and monitoring rheumatoid arthritis. United States Patent US 8,728,730. 2014 May 20.
- LingNC,WangSL,WangD,SinghS,inventors;NestecSA,assignee. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis. United States Patent US 8,519,096. 2013 Aug 27.
- Thompson P, Blumberg H, Chandrasekher YA, Novak JE, inventors; Zymogenetics Inc, assignee. Method of treating rheumatoid arthritis using anti-IL-20 antibodies. United States Patent US 8,728,469. 2014 May 20.
- Trentham DE, Weiner HL, Hafler DA, inventors; Autoimmune Inc, assignee. Method of treating rheumatoid arthritis with type II collagen. United States Patent US 5,399,347. 1995 Mar 21.
- Feldman M, Maini RN, Williams RO, inventors; Kennedy Mathilda, Terence Institute of Rheumatology Trust, assignee. Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti- TNF antibodies. United States Patent US 5,741,488. 1998 Apr 21.
- Van'tklooster GA, Namour FS, Brys RC, Van Rompaey LJ, inventors; Galapagos NV , assignee. Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof. United States Patent US 9,284,311. 2016 Mar 15.
- O'brien PM, Anderson E, Bolton GL, Ferguson DA, Jiang X, Kral Jr RM, Visnick M, inventors; Reata Pharmaceuticals Inc, assignee. Compounds Including an Anti-inflammatory Pharmacore and Methods of use. 2015 Jan 21.
- Menet CJ, Hodges AJ, Vater HD, inventors; Galapagos NV, assignee. Compound useful for the treatment of degenerative and inflammatory diseases. United States Patent US 8,802,682. 2014 Aug 12.
- Medich JR, Ruperto N, Martini A, Lovell DJ, Giannini EH, inventors; AbbVie Biotechnology Ltd, assignee. Uses and Compositions for Treatment of Juvenile Rheumatoid Arthritis. United States Patent application US 14/935,991. 2016 Sep 29.
- Huang X, Jasson M, Marks V, Radin A, Fan C, Van Hoogstraten H, Fiore S, Van Adelsberg J, Genovese M, inventors; Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc, assignee. Compositions for the treatment of rheumatoid arthritis and methods of using same. United States Patent Application US 15/034,531. 2016 Sep 29.
- Palombella VJ, Kutok JL, inventors; Infinity Pharmaceuticals Inc, assignee. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors. United States Patent Application US 13/839,912. 2014 May 1.
- Vakkalanka SK, Viswanadha S, inventors; Rhizen Pharmaceuticals SA, assignee. Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor. United States Patent US 9,737,521. 2017 Aug 22.
- Fisher E, Edwards III C, Kieft G, inventors; Amgen Inc, assignee. Nucleic acids encoding truncated soluble tumor necrosis factor. United States Patent US 7,732,587. 2010 Jun 8.
- Menet CJ, Hodges AJ, Vater HD, inventors; Galapagos NV, assignee. Compound useful for the treatment of degenerative and inflammatory diseases. United States Patent US 8,802,682. 2014 Aug 12.
- Schwaeble HW, Dudler T, Tedford CE, Parent JB, Demopulos GA, inventors; University of Leicester, Omeros Medical Systems Inc, assignee. Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation. United States Patent US 8,652,477. 2014 Feb 18.
- Kesharwani D, Paliwal R, Satapathy T, Paul SD. Rheumatiod arthritis: An updated overview of latest therapy and drug delivery. Journal of Pharmacopuncture. 2019;22(4):210.
- A Detailed Review on Fast Dissolving Niosomal Films for Sublingual Drug Delivery
Authors
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Kangra (H.P.) 177101,, IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 14, No 2 (2022), Pagination: 163-170Abstract
Fast dissolving or Quick-dissolving dosage forms have great importance in the pharmaceutical field due to their special properties and advantages. Fast-dissolving dosage forms breakdown immediately in the salivary fluids of the oral cavity within a minute, where they release the active pharmaceutical ingredient. Sublingual drug delivery system is a novel route of drug administration in which the drug substance is placed under the tongue and is directly absorbed via the blood vessels and produces the immediate onset of action. Noisome are closed bilayer vesicles formed by self-assembly of nonionic surfactant in an aqueous medium. Noisome is similar to liposome but has the ability to increase the stability of the drug. Formulated niosomes are added into the film forming polymers to obtain sublingual niosomal films. Fast dissolving niosomal film is suitable for the drugs which show high first-pass metabolism or hepatic metabolism, low bioavailability drugs, and have a short half life drugs. Fast Dissolving Niosomal Films used to improve the oral bioavailability and reduce the dose and dosing frequency, which reduce systemic side effects and as well as cost-effective. Niosomes allow the prolonged release of the drug and film was used to increase the bioavailability of drugs via the sublingual route of drug administration. Fast dissolving niosomal films have great importance during emergency conditions like allergy, short-term spasm, and asthma whenever an immediate onset of action is required. Fast dissolving films are also suitable for pediatric, geriatric, and dysphasic patients or patients with fear of choking.Keywords
Fast-dissolving drug–delivery, Geriatric, Solvent casting, Pediatric, Bioavailability.References
- Siddiqui, MD Nehal, Garima Garg, and Pramod Kumar Sharma. "A Short Review on “A Novel Approach in Oral Fast Dissolving Drug Delivery System and Their Patents”." Advances in Biological Research 5.6 (2011): 291-303.
- Allam A, Fetih G. Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate. Drug Des Devel Ther. 2016 Aug 2;10: 2421-33. doi: 10.2147/DDDT.S113775. PMID: 27536063; PMCID: PMC4977085.
- Auda SH, Fathalla D, Fetih G, El-Badry M, Shakeel F. Niosomes as transdermal drug delivery system for celecoxib: in vitro and in vivo studies. Polymer Bulletin. 2016 May 1;73(5):1229-45. DOI 10.1007/s00289-015-1544-8
- Frey P. Film strips and pharmaceuticals. Pharma. Mfg. & Packag. Sourcer. 2006:92-3.
- Chien YW. Novel drug delivery systems. Drugs and the pharmaceutical sciences. 1992;50.
- El-Badry M, Fetih G, Fathalla D, Shakeel F. Transdermal delivery of meloxicam using niosomal hydrogels: in vitro and pharmacodynamic evaluation. Pharm Dev Technol. 2015 Nov;20(7):820-826. doi: 10.3109/10837450.2014.926919. Epub 2014 Jun 9. PMID: 24909736.
- Naimish AS, Vipul PP, Devang JP. Sublingual Delivery: A Promising approach to improve Bioavailability. Pharma Science Monitor. 2013 Apr 1;4(2). ISSN: 0976-7908
- Thakur N, Bansal M, Sharma N, Yadav G, Khare P. Overview “a novel approach of fast dissolving films and their patients”. Advances in Biological Research. 2013;7(2):50-8. DOI: 10.5829/idosi.abr.2013.7.2.72134
- Sharma, D., Kaur, D., Verma, S., Singh, D., Singh, M., Singh, G., & Garg, R. (2015). Fast dissolving oral films technology: A recent trend for an innovative oral drug delivery system. International Journal of Drug Delivery, 7(2), 60-75. Retrieved from http://www.arjournals.org/index.php/ijdd/article/view/ 1692
- Arya A, Chandra A, Sharma V, Pathak K. Fast dissolving oral films: an innovative drug delivery system and dosage form. International Journal of ChemTech Research. 2010 Jan; 2(1):576- 83.
- Juluru NS. Fast dissolving oral films: A review. IJAPBC. 2013 Jan;2(1):108-12.
- Allam A, Fetih G. Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate. Drug Des Devel Ther. 2016 Aug 2;10:2421-33. doi: 10.2147/DDDT.S113775. PMID: 27536063; PMCID: PMC4977085.
- Pathan A, Gupta MK, Dubey A, Agrawal A, Jain NK. Fast dissolving oral films: A review. Current Res. in Bio & Pharm Sci. 2015; 4(5):19-26. ISSN: 2349-7750
- Nagar, P. & Chauhan, Iti & Yasir, Mohd. (2011). Insights into polymers: Film formers in mouth dissolving films. Drug Invention Today. 3. 280-289.
- Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release. 2009 Oct 15;139(2):94-107. doi: 10.1016/j.jconrel.2009.06.014. Epub 2009 Jun 24. PMID: 19559740.
- Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clin Ther. 2008 Nov;30(11):2120-32. doi: 10.1016/j.clinthera.2008.11.018. PMID: 19108800; PMCID: PMC2744307.
- McGregor, R., Homan, H., & Gravina, S. (2004). Fast dissolving film delivery of nucleotides that inhibit the unpleasant taste of bitter tasting medications. WO Patent, 19885.
- Rawat, Shilpi, D. V. Derle, Sulbha R. Fukte, Pramod R. Shinde, and Balasaheb S. Parve. "Superdisintegrants: an overview." World journal of pharmacy and pharmaceutical sciences 3, no. 5 (2014): 263-278.
- Ravi Kumar K, Mercy Sulochana M. Fast dissolving films: a unique strategy for drug delivery. Asian J. Pharm. Res. 2014;4(1):47-55. Ravi Kumar K, Mercy Sulochana M. Fast dissolving films: a unique strategy for drug delivery. Asian J. Pharm. Res. 2014;4(1):47-55.
- Patil, S. L., Mahaparale, P. R., Shivnikar, M. A., Tiwari, S. S., Pawar, K. V., & Sane, P. N. (2012). Fast dissolving oral films: An innovative drug delivery system. International journal of Research and Reviews in Pharmacy and Applied science, 2(3), 482-496. ISSN NO. 2271-3681
- Pechová V, Gajdziok J, Muselík J, Vetchý D. Development of Orodispersible Films Containing Benzydamine Hydrochloride Using a Modified Solvent Casting Method. AAPS PharmSciTech. 2018 Aug;19(6):2509-2518. doi: 10.1208/s12249-018-1088-y. Epub 2018 Jun 11. PMID: 29948980.
- Bhyan, Bhupinder & Jangra, S. & Kaur, M. & Singh, H. (2011). Orally fast dissolving films: Innovations in formulation and technology. International Journal of Pharmaceutical Sciences Review and Research. 9. 50-57.
- Lade, M. S., S. A. Payghan, Z. J. Tamboli, and J. I. Disouza. "Polymer based wafer technology: A Review." International Journal of Pharmaceutical and Biological Archives 4, no. 6 (2013): 1060-1074.
- Panda, Bibhu Prasad, N. S. Dey, and M. E. B. Rao. "Development of innovative orally fast disintegrating film dosage forms: a review." International Journal of Pharmaceutical Sciences and Nanotechnology 5, no. 2 (2012): 1666-1674.
- Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67-76. doi:10.4103/2230-973X.114897
- Patel D, Patel M, Upadhyay P, Shah N, Shah S. A Review on Mouth Dissolving Film. J Pharm. Sci. and Bioscientific Res. 2015; 5(3): 266-273. ISSN NO. 2271-3681
- Rathi, Varun, V. Senthil, Lavanya Kammili, and Ritu Hans. "A Brief review on oral film Technology." International Journal of Research in Ayurveda and Pharmacy 2, no. 4 (2011).
- Jyoti, A., Gurpreet, S., Seema, S. and Rana, A.C., 2011. Fast dissolving films: A novel approach to oral drug delivery. International research journal of pharmacy, 2(12), pp.69-74.
- Nagendrakumar, D., Keshavshetti GG, Pratibha Mogale, Swati Swami, and Harshanand Swami. "Formulation and evaluation of fast dissolving oral films of metoprolol sccinate." International Journal of Engineering 6, no. 4 (2015): 8269.
- Gowri, R., N. Narayanan, S. Revathy, P. Prabhavathy, G. Preethy Mol, and G. Rekha. "Melt in mouth films-an effective alternative drug delivery system." Int J Bio and Pharm Res 4, no. 9 (2013): 645-650.
- Karthikeyan, D., Sanju Sri, and C. Santhosh Kumar. "Development of fast dissolving oral film containing of rizatriptan benzoate as an antimigraine medication." Indo American Journal of Pharmaceutical Research 3, no. 3 (2013): 2642-2654.
- Felton, Linda A., Patrick B. O’Donnell, and James W. McGinity. "Mechanical properties of polymeric films prepared from aqueous dispersions." In Aqueous polymeric coatings for pharmaceutical dosage forms, pp. 125-148. CRC Press, 2008.
- Fulzele, S. V., Satturwar, P. M., andDorle, A. K. (2002). Polymerized rosin: novel film forming polymer for drug delivery. International journal of pharmaceutics, 249(1-2), 175-184. https://doi.org/10.1016/S0378-5173(02)00529-X
- Patel, R. S., and Poddar, S. S. (2009). Development and characterization of mucoadhesive buccal patches of salbutamol sulphate. Current drug delivery, 6(1), 140-144. DOI: https://doi.org/10.2174/156720109787048177
- Patel D, Patel M, Upadhyay P, Shah N, Shah S. A Review on Mouth Dissolving Film. J Pharm. Sci. and Bioscientific Res. 2015; 5(3): 266-273.
- Nair, Sreeja C., and K. R. Anoop. "Design and in vitro evaluation of controlled release satranidazole subgingival films for periodontitis therapy." Int J Pharm Sci Rev Res 24, no. 1 (2014): 8-14.
- Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013 Apr;3(2):67-76. doi: 10.4103/2230-973X.114897. PMID: 24015378; PMCID: PMC3757902.
- D. Archana J, Vijaya V, Dr. Uma MR, Formulation and evaluation of oral thin films containing saxagliptin, IJJIPSR, 2, 2014, 2669- 2690.
- Peppas, Nikolaos and Buri, Pierre. (1985). Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. Journal of Controlled Release. 2. 257-275. 10.1016/0168-3659(85)90050- 1.
- Meathrel, B., and Moritz, C. A. T. H. Y. (2007). Dissolvable films and their potential in IVDs. IVD Technol, 13(9), 53-58.
- Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release. 2009 Oct 15;139(2):94-107. doi: 10.1016/j.jconrel.2009.06.014. Epub 2009 Jun 24. PMID: 19559740.
- Vishwkarma, D. and Tripathi, A. and Yogesh, P. and Maddheshiyab, B. (2011). Review article on mouth dissolving film. J Glob Pharm Technol. 3. 10.1234/jgpt.v3i1.335.
- Application of Berberine on Skin Diseases: A Review
Authors
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
2 Department of Pharmaceutical Analysis and Quality Assurance, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 14, No 4 (2022), Pagination: 304-308Abstract
The plants containing berberine have been used for the treatment of skin diseases, inflammatory disorders, and reducing fevers, wound healing, digestive and respiratory diseases and in treatment of tumors. By taking the specific properties of the berberine, this review describes the method mentioned in the literature regarding the berberine extraction. Furthermore, many experimental and clinical studies suggest that berberine has several pharmacological activities such as antioxidative, cardioprotective, nephroprotective, and hepatoprotective effect. This review summarizes the information about botanical occurrence, traditional uses and pharmacological effects of berberine and berberine containing plants.Keywords
Berberine, Skin Diseases, Psoriasis.References
- Chen Y Y, Chang F R, Wu Y C. Isoquinoline alkaloids and lignans from Rollinia mucosa. Journal of Natural Products. 1996; 59: 904-906.
- Singh A, Duggal S, Kaur N, Singh J. Berberine: Alkaloid with wide spectrum of pharmacological activities. J. Nat. Prod.2010; 3: 64–75.
- Dev S. A Selection of Prime Ayurvedic Plants Drugs ancientModern Concordance. New Delhi: Anamaya Publishers; 2006.
- Kirtikar K R, Basu B D. Indian Medicinal Plants. Allahabad : CSIR Publications. 1998;1.
- Kataoka M, Tokuyama E, Miyananga Y, Uchida T. The taste sensory evaluation of medicinal plants and Chinese medicines. Int. J. Pharm. 2008; 36–44.
- Fabricant D S, Famsworth N R. The value of plants used in traditional medicine for drug discovery. Journal of Environmental Health Perspectives. 2005; 69.
- Rosjanga P, Gritsanapan W. Variation of berberine content in the Coscinium fenestratum Stem in Thailand Market. Mahidol University Journal of Pharmaceutical Sciences. 2005;32: 66-70
- Andola H C, Gaira K S, Rawal M S, Bhatt I D, Purohit V K. Variations of berberine content of Berberis asiatica. Western Himalaya Chem Biodiversity. (2010a) ; 7:415-420.
- Andola H C, Rawal R S, Rawat M S M, Bhatti I D, Purohit V K. Variations of berberine contents in Berberis pseudumbellata. A High Value Medicinal shrub of West Himalaya. India Medicinal plants Journal of Phytomedicines and related industries. (2010b); 2: 111-115.
- Tome F, Colombo M L. Distribution of alkaloids in Chelidonium majus and factor affecting their accumulation. Phytochemistry. 1995; 37-39.
- Chandra P, Purohit A N. Berberine contents and alkaloid profile of Berberis species from different altitudes. Biochemistry systems Ecology. 1980; 379-380.
- Mikage M, Mouri C. Pharmacognostical studies of Berberis plants from Nepal (1) altitudinal, interspecific and partial variations of berberine content in the barks. Pharmaceutics; 249-254.
- Marek R, Seckarova P, Hulova D, Marek J, Dostal J, Sklenar V. Palmatine and Berberine isolation artifacts. Journal Of Natural Products. 2003; 66: 481-486.
- Grycova L, Dostal J, Marek R. Quaternary protoberberine alkaloids. Phytochemistry. 2007; 68: 150-175.
- Rahal A, Kumar A, Singh V, Yadav B, Tiwari R, Chakrobarty S. The Interplay: Oxidative stress, pro-oxidants and oxidants. Biomedical Research International. 2014.
- Thirupurasundari C J, Padmini R, Devaraj S N. Effect of berberine on antioxidant status, ultrastructural modifications and protein bound carbohydrates in azoxymethane- induced colon cancer in rats. Journal of Chemistry Biological Int. 2009; 177: 190-195.
- Zeng X. Relationship between the clinical effects of berberine on severe congestive heart failure and its concentration in plasma studies by HPLC. Biomedical Chromatogram. 1999; 13: 442-444.
- Chi L, Peng L, Pan N, Hu X, ZhangY, The anti-atherogenic effects of berberine of foam cell formation mediated through upregulation of sirutin I. International Journal of Molecular Medicines. 2014; 34: 1087-1093.
- Cicero A, Ertek S. Berberine: Metabolic and cardiovascular effects in preclinical and clinical trials. Journal of Nutraceuticals Diet Supplement. 2009; 1: 1-10.
- Chang T Y, Li B L, Chang C C, Urano Y. Acyl-coenzyme A: Cholesterol acyltransferases. Journal of Physiology- endocrinology and metabolism. 2009; E1-E9.
- Wang Y, Yi X, Ghanam K, Zhang S, Zhao T, Zhu X. Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. Mrtabolism 2014; 63: 1167-1177.
- Yin J, Gao Z, Liu, D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Journal of Physiology- endocrinology and metabolism. 2008; 148-156.
- Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y. Berberine improves glucose metabolism in diabetic rat by ingibition of hepatic gluconeogenesis. 2011.
- Chen Y, Wang Y, Lin L, Zhang Y, Sun C, Lopez A. Berberine improves glucose homeostasis in streptozotocin- induced diabetic rats in association with multiple factors of insulin resistance. ISRN Endorinol. 2011; 1-8.
- Dai P, Wang J, Lin L, Zhang Y, Wang Z. Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with TypeII Diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography. Journal of experimental and therapeutic Medicine. 2015; 10: 869-876.
- Zhao X, Zhang J, Tong N, Chen Y, Luo Y. Protective effects of berberine on Doxorubicin- induced hepatotoxicity in mice. Journal of Biological and Pharmaceutical Bulletin. 2012; 35: 796-800.
- Domitrovic R, Jakovac H, Blagojevic G. Hepatoprotective activity of berberine mediated by inhibition of TNF-α, COX-2 expression in CCl4-intoxicated mice. Toxicology. 2011; 33-43.
- Kim S, Chung J H. Berberine prevents UV-induced MMP-I and reduction of type-I procollagen expression in human dermal fibroblasts. Phytomedicine.2008; 15: 749-753.
- Yahki K, Kiso A, Zhou Y Y. Abstracts: The effects of Coptis japonica root extract and its key component, berberine on human subcutaneous adipocytes. International Journal of Cosmetic Sciences. 2010; 32: 392-395.
- Derosa G, Maffioli P, Cicero A F. Berberine on Metabolic and Cardiovascular risk factors: An analysis from preclinical evidences to clinical trials. Expert Opinion Biomolecular Theory. 2012; 12: 1113-1124.
- Fouladi R F. 2012. Aqueous extract of dried fruit of berberis vulgaris L. in acne vulgaris, a clinical trial. Journal of Dietary Supplement. 2012; 9: 253-261.
- Johnson M, Rafikhah N. Berberis vulgaris juice and acne vulgaris: a placebo-controlled study. Asian Journal of Clinical Nutrition. 2014; 6: 47-52.
- Gupta DK, Aqil M, Sultana Y. Tailoring of berberine loaded transniosomes for the management of skin cancer in mice. Journal of Drug Delivery Science and Technology. 2020; 60: 1-13.
- Torky AS, Maha MA, Abdallah AY. Novel skin penetrating berberine oleate complex capitalizing on hydrophobic ion pairing approach. International Journal of Pharmaceutics. 2018; 76-86.
- Vanti G, Wang M, Billia AR. Hydroxypropyl methylcellulose hydrogel of berberine chlorideloaded escinosomes: Dermal absorption and biocompatibility. International Journal of Biological Macromolecule. 2020; 1-29.
- Niu J, Yuan M, Chen C, Wang L, Gan Y. Berberine-Loaded Thiolated Pluronic F127 Polymeric Micelles for Improving Skin Permeation and Retention. International Journal of Nanomedicine.2020; 1-19.
- Lin H, Lim L, Choi Y. Development and in-vitro evaluation of coloaded berberine chloride and evodiamine ethosomes for treatment of melanoma. International Journal of Pharmaceutics. 2020; 1-7.
- Vanti G, Bani D, Salvatici CM, Bergonzi MC, Billia AR. Development and Percutaneous Permeation Study of Escinosomes, Escin-Based Nanovesicles Loaded with Berberine Chloride. Pharmaceutics. 2019; 1-22.
- Gull A, Ahmed S, Ahmed FS, Chandra. Hydrogel thickened microemulsion; a local cargo for the co- delivery of cinnamaldehyde and berberine to treat acne vulgaris. Journal of Drug Delivery Science and Technology. 2020; 58: 1-10
- Amato G, Grimaudo MA, Lorenzo CA, Carbone C, Musumeci T. Hyaluronan/Poly-L-lysine/Berberine Nanogels for Impaired Wound Healing. Pharmaceutics. 2020; 1-11.
- Mayangsari F, Surini S, Iswandana R. Development of transfersomal emulgel to enhance the permeation of berberine chloride for transdermal delivery. Journal of Applied Pharmaceutical Science. 2022; 12(02): 48-55.
- Awate P S, Pimple T P, Pananchery JF, Jain A S. Formulation and evaluation of berberine hcl as niosomal drug delivery system. Asian Journal of Pharmaceutical Research. 2020; 10(3).
- Rahamat U, Kumar P M, Gella S. Psoriasis: A comprehensive Review. Asian J. of Res.in Pharma. Sciences. 2019; 9(1): 29-38.
- Mahajan T, Singh N, Goyal K, Jindal S, Pandit V, Ashawat MS. Recent updates on Psoriasis: A Review. Asian Journal of Pharmaceutical research. 2022; 12(1): 3-76.
- Singh N, Sondhi S, Jindal S, Pandit V, Ashawat MS. Treatment and Management for patients with mild to severe Psoriasis: A Review. Asian Journal of Pharmaceutical Research. 2020; 10(4):286-292.
- Sondhi S, Singh N, Jindal S. Natural Remedies used in treatment of Psoriasis: A Short review. Asian Journal of Pharmaceutical Research. 2021; 11(1): 43-45.
- Sharma S, Sharma R, Goyal K, Jindal S. Potential of herbal treatment of Psoriasis: A Laconic Review. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(1): 51-57.
- Sondhi S, Singh N, Goyal K, Jindal S. Development of Topical Herbal gel of Berberine Hydrochloride for the treatment of Psoriasis. 2021; 13(1): 12-18.
- Verma D, Samal P K. Evaluation of Synergistic analgesic Activity of Berberine and Asiatic Acid in Mice. Research Journal of Pharmacy and Technology. 2020; 13(12): 6081-6085.
- Singh N, Goyal K, Sondhi S, Jindal S. Traditional and medicinal use of Barbaloin: Potential for the Management of Various Disease. 2020; 8(3): 21-30.
- Singh N, Goyal K, Sondhi S, Jindal S. Development and characterization of Barbaloin Gel for the safe and effective treatment of Psoriasis. Journal of Drug Delivery and Therapeutics. 2020; 10(5): 188-197.
- Fusidic Acid: A Therapeutic Review
Authors
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalaji, Distt. Kangra (H.P.) India., IN
2 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalaji, Distt. Kangra (H.P.) India, IN
3 1Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalaji, Distt. Kangra (H.P.) India, IN
4 Department of Pharmaceutical Analysis and Quality Assurance, Laureate Institute of Pharmacy, Kathog, Jawalaji, Distt. Kangra (H.P.) India., IN
5 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalaji, Distt. Kangra (H.P.) India ., IN
Source
Asian Journal of Research in Chemistry, Vol 15, No 5 (2022), Pagination: 372 - 380Abstract
Fusidic acid (FA), derived from the fungus Fusidium coccineum, is an antimicrobial agent that inhibits bacterial protein synthesis by preventing EF-G translocation. This review will provide information regarding the properties of FA, as well as studies on its clinical efficacy in skin and soft-tissue infections (SSTIs). FA has been used for treatment of infection caused by gram- positive microorganism. FA cream or ointment are clinically effective and shown minimum adverse reaction when used in SSTIs two or three times regularly. The analytical methods which describe the presence of FA in biological samples and pharmaceutical formulations are reviewed in this article. High-performance liquid chromatography has been widely used analytical method in the analysis of FA, as it can reduce the cost as well as time of analysis. This review also includes the information regarding the randomised trials which investigates the clinical efficacy of fusidic acid in dermatology in comparative trials that were discovered.Keywords
High-performance liquid chromatography, Gram- positive microorganism.References
- Kim S, Covington A, Pamer EG. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. Immunol Rev. 2017;279(1):90–105.
- Fisher RA, Gollan B, Helaine S. Persistent bacterial infections and persister cells. Nat Rev Microbiol. 2017;15(8):453–64.
- Russell AD. Biocide use and antibiotic resistance: the relevance of laboratory findings to clinical and environmental situations. Lancet Infect Dis. 2003;3(12):794–803.
- Kumar U, Narang R, Nayak SK, Singh SK, Gupta V. Benzimidazole: Structure Activity Relationship and Mechanism of Action as Antimicrobial Agent. Res J Pharm Technol. 2017;10(7):2400–14.
- Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science (80). 2009;325(5944):1089–93.
- Gerarden TD, Newell RG, Stavins RN. Assessing the energy-efficiency gap.J Econ Lit. 2017;55(4):1486–525.
- Lippi G, Chance JJ, Church S, Dazzi P, Fontana R, Giavarina D, et al. Preanalytical quality improvement: from dream to reality. Clin Chem Lab Med. 2011;49(7):1113–26.
- Sonawane L V, Poul BN, Usnale S V, Waghmare P V, Surwase LH. Bioanalytical method validation and its pharmaceutical application-a review. Pharm Anal Acta. 2014;5(288):2.
- Curbete MM, Salgado HRN. A critical review of the properties of fusidic acid and analytical methods for its determination. Crit Rev Anal Chem. 2016;46(4):352–60.
- Barbosa-Filho JM, Nascimento Júnior FA do, Tomaz AC de A, AthaydeFilho PF de, Silva MS da, Cunha E V, et al. Natural products with antileprotic activity. Rev Bras Farmacogn. 2007;17(1):141–8.
- Zhao M, Gödecke T, Gunn J, Duan J-A, Che C-T. Protostane and fusidane triterpenes: a mini-review. Molecules. 2013;18(4):4054–80.
- Werner AH, Russell AD. Mupirocin, fusidic acid and bacitracin: activity, action and clinical uses of three topical antibiotics. Vet Dermatol. 1999;10(3):225–40.
- Fujii T, Nakada M. Stereoselective construction of the ABC-ring system of fusidane triterpenes via intermolecular/transannular Michael reaction cascade. Tetrahedron Lett. 2014;55(9):1597–601.
- Li C, Li XZ, Graham N, Gao NY. The aqueous degradation of bisphenol A and steroid estrogens by ferrate. Water Res. 2008;42(1–2):109–20.
- Wudy SA, Schuler G, Sánchez-Guijo A, Hartmann MF. The art of measuring steroids: principles and practice of current hormonal steroid analysis. J Steroid Biochem Mol Biol. 2018;179:88–103.
- Buetow DE, Levedahl BH. Responses of microorganisms to sterols and steroids. Annu Rev Microbiol. 1964;18(1):167–94.
- Gehrig KA, Warshaw EM. Allergic contact dermatitis to topical antibiotics: epidemiology, responsible allergens, and management. J Am Acad Dermatol. 2008;58(1):1–21.
- Frimodt-Møller N. 74 Fusidic Acid (Fusidate Sodium). USE Antibiot. 2010;945.
- Karauzum H, Venkatasubramaniam A, Adhikari RP, Kort T, Holtsberg FW, Mukherjee I, et al. IBT-V02: a multicomponent toxoid vaccine protects against primary and secondary skin infections caused by Staphylococcus aureus. Front Immunol. 2021;12:475.
- Singer AJ, Talan DA. Management of skin abscesses in the era of methicillin-resistant Staphylococcus aureus. N Engl J Med. 2014;370(11):1039–47.
- Revathi K. Contact Allergies in Patients with Leg Ulcers. PSG Institute of Medical Sciences and Research, Coimbatore; 2015.
- Larsen FS, Simonsen L, Melgaard A, Wendicke K, Henriksen AS. An efficient new formulation of fusidic acid and betamethasone 17-valerate (Fucicort® Lipid cream) for treatment of clinically infected atopic dermatitis. Acta Derm Venereol. 2007;87(1):62–8.
- Girolomoni G, Mattina R, Manfredini S, Vertuani S, Fabrizi G. Fusidic acid betamethasone lipid cream. Int J Clin Pract. 2016;70:4–13.
- Bryskier A. Fusidic acid. Antimicrob Agents Antibacterials Antifung. 2005;631–41.
- Ragab AE, Ibrahim A-RS, Léon F. 3-O-Formyl-27-Hydroxyfusidic Acid: A New Metabolite of Fusidic Acid by Cunninghamella echinulata. Rec Nat Prod. 2020;14(4):296.
- Gaohua L, Miao X, Dou L. Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity. Expert Opin Drug Metab Toxicol. 2021;17(9):1103–24.
- Shriner RL, Hermann CKF, Morrill TC, Curtin DY, Fuson RC. The systematic identification of organic compounds. John Wiley & Sons; 2003.
- Morgan PW, Kwolek SL. Low temperature solution polycondensation of piperazine polyamides. J Polym Sci Part A Gen Pap. 1964;2(1):181–208.
- Zembower TR, Noskin GA, Postelnick MJ, Nguyen C, Peterson LR. The utility of aminoglycosides in an era of emerging drug resistance. Int J Antimicrob Agents. 1998;10(2):95–105.
- Bhagwat SS, Nandanwar M, Kansagara A, Patel A, Takalkar S, Chavan R, et al. Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence. Drug Des Devel Ther. 2019;13:4351.
- Dziwornu GA, Kamunya S, Ntsabo T, Chibale K. Novel antimycobacterial C-21 amide derivatives of the antibiotic fusidic acid: synthesis, pharmacological evaluation and rationalization of media-dependent activity using molecular docking studies in the binding site of human serum albumin. Medchemcomm. 2019;10(6):961–9.
- Peske F, Savelsbergh A, Katunin VI, Rodnina M V, Wintermeyer W. Conformational changes of the small ribosomal subunit during elongation factor G-dependent tRNA–mRNA translocation. J Mol Biol.
- ;343(5):1183–94.
- Musmade PB, Tumkur A, Trilok M, Bairy KL. Fusidic acid–Topical antimicrobial in the management of Staphylococcus aureus. Int J Pharm Pharm Sci. 2013;5:381–90.
- Ward A, Campoli-Richards DM. Mupirocin. Drugs. 1986;32(5):425–44.
- Cé R, Pacheco BZ, Ciocheta TM, Barbosa FS, de CS Alves A, Dallemole DR, et al. Antibacterial activity against Gram-positive bacteria using fusidic acid-loaded lipid-core nanocapsules. React Funct Polym. 2021;162:104876.
- Mohamed MF, Abdelkhalek A, Seleem MN. Evaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular Staphylococcus aureus. Sci Rep. 2016;6(1):1–14.
- Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care.Can J Infect Dis Med Microbiol. 2008;19(2):173–84.
- Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis.
- ;37(10):1298–303.
- Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents. 1999;12:S35–44.
- Thakur K, Sharma G, Singh B, Chhibber S, Katare OP. Nano-engineered lipid-polymer hybrid nanoparticles of fusidic acid: an investigative study on dermatokinetics profile and MRSA-infected burn wound model. Drug Deliv Transl Res. 2019;9(4):748–63.
- Cassir N, Rolain J-M, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol. 2014;5:551.
- Garner JS, Committee HICPA. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol. 1996;17(1):54–80.
- Maisch T, Szeimies R-M, Jori G, Abels C. Antibacterial photodynamic therapy in dermatology. Photochem Photobiol Sci. 2004;3(10):907–17.
- Nishijima S, Namura S, Kawai S, Akamatsu H, Asada Y, Kawabata S. Sensitivity of Staphylococcus aureus and Streptococcus pyogenes isolated from skin infections in 1992 to antimicrobial agents. J Dermatol.1994;21(4):233–8.
- Chiller K, Selkin BA, Murakawa GJ. Skin microflora and bacterial infections of the skin. In: Journal of Investigative Dermatology Symposium Proceedings. Elsevier; 2001. p. 170–4.
- Casillas-Vargas G, Ocasio-Malavé C, Medina S, Morales-Guzmán C, Del Valle RG, Carballeira NM, et al. Antibacterial fatty acids: An update of possible mechanisms of action and implications in the development of the next-generation of antibacterial agents. Prog Lipid Res. 2021;82:101093.
- Savelsbergh A, Rodnina M V, Wintermeyer W. Distinct functions of elongation factor G in ribosome recycling and translocation. Rna.2009;15(5):772–80.
- Gupta A, Mir SS, Saqib U, Biswas S, Vaishya S, Srivastava K, et al. The effect of fusidic acid on Plasmodium falciparum elongation factor G (EF-G).Mol Biochem Parasitol. 2013;192(1–2):39–48.
- Shi X, Khade PK, Sanbonmatsu KY, Joseph S. Functional role of the sarcin–ricin loop of the 23S rRNA in the elongation cycle of protein synthesis. J Mol Biol. 2012;419(3–4):125–38.
- Baca OG, Rohrbach MS, Bodley JW. Studies on translocation. 22. Equilibrium measurements of the interactions of guanine nucleotides with Escherichia coli elongation factor G and the ribosome. Biochemistry.1976;15(21):4570–4.
- Nissen P, Kjeldgaard M, Thirup S, Polekhina G, Reshetnikova L, Clark BFC, et al. Crystal structure of the ternary complex of Phe-tRNAPhe, EFTu, and a GTP analog. Science (80- ). 1995;270(5241):1464–72.
- Kinzy TG, Woolford Jr JL. Increased expression of Saccharomyces cerevisiae translation elongation factor 1 alpha bypasses the lethality of a TEF5 null allele encoding elongation factor 1 beta. Genetics.
- ;141(2):481–9.
- Song JM. Genetic and molecular studies of genes that affect translational fidelity in Saccharomyces cerevisiae. University of Illinois at Chicago; 1987.
- Sharma S, Sharma R, Goyal K, Jindal S. Potential of herbal treatment of Psoriasis: A Laconic Review. Asian J Res Pharm Sci. 2021;11(1):51–7.
- Sondhi S, Singh N, Goyal K, Jindal S. Development of topical herbal gel of berberine hydrochloride for the treatment of psoriasis. Res J Pharm Dos Forms Technol. 2021;13(1):12–8.
- Sondhi S, Singh N, Jindal S. Natural Remedies used in the Treatment of Psoriasis: A short Review. Asian J Pharm Res. 2021;11(1):43–5.
- Mahajan T, Singh N, Goyal K, Jindal S, Pandit V, Ashawat MS. Recent Updates on Psoriasis: A Review Tejasavi Mahajan1, Navdeep Singh1, Kamya Goyal2, Shammy Jindal1*, Vinay Pandit1, MS Ashawat1 1Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog Jawalaji Dist-Kangra (HP) India. 2Department of Pharmaceutical Analysis and Quality Assurance, Laureate Institute of Pharmacy, Kathog Jawalaji Dist-Kangra (HP) India.* Corresponding Author E-mail: shammyjindal@ gmail. com. Asian J Pharm Res. 2022;12(1):76–83.
- Singh N, Sondhi S, Jindal S, Pandit V, Ashawat MS. Treatment and Management for patients with mild to severe Psoriasis: A Review. Asian J Pharm Res. 2020;10(4):286–92.
- Singh N, Goyal K, Sondhi S, Jindal S. Development and Characterization of Barbaloin Gel for the Safe and Effective Treatment of Psoriasis. J Drug Deliv Ther. 2020;10(5):188–97.
- Vani PB, Kumar PR. A Comparative Review on Conventional and Traditional medicine in the Treatment of Psoriasis. Res J Pharm Technol. 2020;13(11):5642–6.
- Yadav K, Singh D, Singh MR. Development and Characterization of Corticosteroid loaded Lipid carrier system for Psoriasis. Res J Pharm Technol. 2021;14(2):966–70.
- Thomas J, Parimalam K. Treating pediatric plaque psoriasis: challenges and solutions. Pediatr Heal Med Ther. 2016;7:25.
- Kulawik-Pióro A, Miastkowska M. Polymeric gels and their application in the treatment of psoriasis vulgaris: a review. Int J Mol Sci.2021;22(10):5124.
- Ramanunny AK, Wadhwa S, Singh SK, Sharma DS, Khursheed R, Awasthi A. Treatment strategies against psoriasis: principle, perspectives and practices. Curr Drug Deliv. 2020;17(1):52–73.
- Chen L, Zhou L, Wang C, Han Y, Lu Y, Liu J, et al. Tumor‐targeted drug and CpG delivery system for phototherapy and docetaxel‐enhanced immunotherapy with polarization toward M1‐type macrophages on triple negative breast cancers. Adv Mater. 2019;31(52):1904997.
- Porro GB, Parente F. Side effects of anti-ulcer prostaglandins: an overview of the worldwide clinical experience. Scand J Gastroenterol. 1989;24(sup164):224–31.
- Christiansen K. Fusidic acid adverse drug reactions. Int J Antimicrob Agents. 1999;12:S3–9.
- Enjalbert F, Rapior S, Nouguier-Soulé J, Guillon S, Amouroux N, Cabot C. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol. 2002;40(6):715–57.
- Biswas M, Owen K, Jones MK. Hypocalcaemia during fusidic acid therapy. J R Soc Med. 2002;95(2):91–3.
- Lee WM, Larson AM, Stravitz RT. AASLD position paper: the management of acute liver failure: update 2011. Hepatology. 2011;55(3):965–7.
- Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol. 2008;86(1):5– 17.
- Long BH. 2. Fusidic acid in skin and soft-tissue infections. Acta Derm Venereol. 2008;
- Principi N, Argentiero A, Neglia C, Gramegna A, Esposito S. New antibiotics for the treatment of acute bacterial skin and soft tissue infections in pediatrics. Pharmaceuticals. 2020;13(11):333.
- Njoroge M, Kaur G, Espinoza-Moraga M, Wasuna A, Dziwornu GA, Seldon R, et al. Semisynthetic antimycobacterial C-3 Silicate and C-3/C-21 ester derivatives of fusidic acid: Pharmacological evaluation and stability studies in liver microsomes, rat plasma, and mycobacterium tuberculosis culture. ACS Infect Dis. 2019;5(9):1634–44.
- Ballard BE. Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. J Pharm Sci. 1968;57(3):357–78.
- Goossens A, Gonçalo M. Contact allergy to topical drugs. Contact Dermatitis. 2020;1–37.
- Griffin JP, D’Arcy PF. A manual of adverse drug interactions. Elsevier; 1997.
- Roberts CJC. Clinical Pharmacological Considerations. In: Gastrointestinal Disease. Springer; 1983. p. 155–68.
- Petitjean O, Nicolas P, Tod M, Padoin C, Jacolot A. Drug Interactions during Anti‐Infective Treatments. Antimicrob agents antibacterials Antifung. 2005;1320–52.
- Pryor JB, Lockridge J, Olyaei AJ. The Principles of Drug Dosing in Peritoneal Dialysis. In: Applied Peritoneal Dialysis. Springer; 2021. p. 349– 74.
- Turner P, Volans G, Wiseman H. Approved Names. In: Drugs Handbook 1992–93. Springer; 1992. p. 1–100.
- Neuman M. Useful and Harmful Interactions of. 1985; 83. Frohlich S, Ryan T, Fagan C. Statin therapy associated with fatal rhabdomyolysis. J Intensive Care Soc. 2011;12(1):40–2.
- Jain KK. Drug-induced myopathies. In: Drug-induced Neurological Disorders. Springer; 2021. p. 493–509.
- Singh B. Major concerns on antibiotic resistance and antibiotic-induced complications–paradigm shift to nanaoscale and secondary metabolites from edible plants for rapid killing of bacteria as an imperative.
- Shafran SD, Tyring SK, Ashton R, Decroix J, Forszpaniak C, Wade A, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol. 2004;29(4):248–53.
- Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents. 1999;12:S59–66.
- Török E, Somogyi T, Rutkai K, Iglesias L, Bielsa I. Fusidic acid suspension twice daily: a new treatment schedule for skin and soft tissue infection in children, with improved tolerability. J Dermatolog Treat. 2004;15(3):158– 63.
- Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindström V, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem. 1994;40(10):1921–6.
- Read TRH, Jensen JS, Fairley CK, Grant M, Danielewski JA, Su J, et al. Use of pristinamycin for macrolide-resistant Mycoplasma genitalium infection. Emerg Infect Dis. 2018;24(2):328.
- Raz R, Naber KG, Raizenberg C, Rohana Y, Unamba-Oparah I, Korfman G, et al. Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women. Eur J Clin Microbiol Infect Dis. 2000;19(5):327–31.
- Geerdes-Fenge HF, Goetschi B, Rau M, Borner K, Koeppe P, Wettich K, et al. Comparative pharmacokinetics of dirithromycin and erythromycin in normal volunteers with special regard to accumulation in polymorphonuclear leukocytes and in saliva. Eur J Clin Pharmacol. 1997;53(2):127–33.
- Bradshaw CS, Twin J, Bissessor M, Read TRH, Jensen JJ, Fairley CK, et al. 006.1 The efficacy of pristinamycin for mycoplasma genitalium–an increasing multidrug resistant pathogen. BMJ Publishing Group Ltd; 2015.
- Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis. 1998;27(4):711– 3.
- Doudoulakakis A, Spiliopoulou I, Spyridis N, Giormezis N, Kopsidas J,Militsopoulou M, et al. Emergence of a Staphylococcus aureus clone resistant to mupirocin and fusidic acid carrying exotoxin genes and causing mainly skin infections. J Clin Microbiol. 2017;55(8):2529–37.
- Gibson JR. Trimethoprin-polymyxin B ophthalmic solution in the treatment of presumptive bacterial conjunctivitis—A multicentre trial of its efficacy versus neomycin–polymyxin B-gramicidin and chloramphenicol ophthalmic solutions. J Antimicrob Chemother. 1983;11(3):217–21.
- Hamann K, Thorn P. Systemic or Local Treatment of Erythrasma? A comparison between Erythromycin Tablets and FucidinR Cream in General Practice. Scand J Prim Health Care. 1991;9(1):35–9.
- Cole C, Gazewood JD. Diagnosis and treatment of impetigo. Am Fam Physician. 2007;75(6):859–64.
- Qin X, Song M, Ma H, Yin C, Zhong Y, Zhang L, et al. Low‐temperature bleaching of cotton fabric with a binuclear manganese complex of 1, 4, 7‐ trimethyl‐1, 4, 7‐triazacyclononane as catalyst for hydrogen peroxide. Color Technol. 2012;128(5):410–5.
- Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, Pyon J-K, Wa CTC, Villa MA. Povidone iodine in wound healing: A review of current concepts and practices. Int J Surg. 2017;44:260–8.
- Meaney-Delman D, Bartlett LA, Gravett MG, Jamieson DJ. Oral and intramuscular treatment options for early postpartum endometritis in lowresource settings: a systematic review. Obstet Gynecol. 2015;125(4):789– 800.
- Heydari R, Mousavi M. Simultaneous determination of saccharine, caffeine, salicylic acid and benzoic acid in different matrixes by salt and air-assisted homogeneous liquid-liquid extraction and high-performance liquid chromatography. J Chil Chem Soc. 2016;61(3):3090–4.
- Lodha R, Randev S, Kabra SK. Oral antibiotics for community–acquired pneumonia with chest-indrawing in children aged below five years: A Systematic Review. Indian Pediatr. 2016;53(6):489–95.
- Ma Y, Zhang N, Wu S, Huang H, Cao Y. Antimicrobial activity of topical agents against Propionibacterium acnes: an in vitro study of clinical isolates from a hospital in Shanghai, China. Front Med. 2016;10(4):517–21.
- Morley PAR, Munot LD. A comparison of sodium fusidate ointment and mupirocin ointment in superficial skin sepsis. Curr Med Res Opin.1988;11(2):142–8.
- Golan Y. Current treatment options for acute skin and skin-structure infections. Clin Infect Dis. 2019;68(Supplement_3):S206–12.
- Stulberg DL, Penrod MA, Blatny RA. Common bacterial skin infections. Am Fam Physician. 2002;66(1):119.
- Denton M, O’Connell B, Bernard P, Jarlier V, Williams Z, Henriksen AS. The EPISA study: antimicrobial susceptibility of Staphylococcus aureus causing primary or secondary skin and soft tissue infections in the
- community in France, the UK and Ireland. J Antimicrob Chemother. 2008;61(3):586–8.
- Kakar N, Kumar V, Mehta G, Sharma RC, Koranne R V. Clinico‐bacteriological study of pyodermas in children. J Dermatol. 1999;26(5):288–93.
- Oranje AP, Chosidow O, Sacchidanand S, Todd G, Singh K, Scangarella N, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study.Dermatology. 2007;215(4):331–40.
- Wollenberg A, Christen‐Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin‐ Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatology Venereol. 2020;34(12):2717–44.
- Sibbald RG, Orsted H, Schultz GS, Coutts P, Keast D. Preparing the wound bed 2003: focus on infection and inflammation. Ostomy Wound Manag. 2003;49(11):24–51.
- Chu AC. 4. Antibacterial/steroid combination therapy in infected eczema. Acta Derm Venereol. 2008;
- Poyner TF, Dass BK. Comparative efficacy and tolerability of fusidic acid/hydrocortisone cream (Fucidin® H cream) and miconazole/hydrocortisone cream (Daktacort® cream) in infected eczema. J
- Eur Acad Dermatology Venereol. 1996;7:S23–30.
- Rangegowda SM, Madhavrao D, Gunjahalli B, Shetty P, Ravikumar BC. Archives of Clinical & Experimental Dermatology. 2021;
- Hill VA, Wong E, Corbett MF, Menday AP. Comparative efficacy of betamethasone/clioquinol (Betnovate-C) cream and betamethasone/fusidicacid (Fucibet) cream in the treatment of infected hand eczema. J Dermatolog Treat. 1998;9(1):15–9.
- Bratovčić A, Odobašić A, Ćatić S. The advantages of the use of ionselective potentiometry in relation to UV/VIS spectroscopy. Agric Conspec Sci. 2009;74(3):139–42.
- Saleh GA, Askal HF, Darwish IA, El-Shorbagi A-NA. Spectroscopic analytical study for the charge-transfer complexation of certain cephalosporins with chloranilic acid. Anal Sci. 2003;19(2):281–7.
- Nakra S, Green RJ, Anderson SL. Thermal decomposition of JP-10 studied by micro-flowtube pyrolysis-mass spectrometry. Combust Flame.2006;144(4):662–74.
- Basner R, Schmidt M, Denisov E, Becker K, Deutsch H. Absolute total and partial cross sections for the electron impact ionization of tetrafluorosilane (SiF 4). J Chem Phys. 2001;114(3):1170–7.
- Al-Shaalan NH. Atomic absorption spectrometric determination of fusidic acid in bulk powder and in pharmaceutical dosage form. J Chem Pharm Res. 2010;2:135–43.
- Moradi M, Kashanaki R, Borhani S, Bigdeli H, Abbasi N, Kazemzadeh A. Optimization of supramolecular solvent microextraction prior to graphite furnace atomic absorption spectrometry for total selenium determination in food and environmental samples. J Mol Liq. 2017;232:243–50.
- Pedraza A, Sicilia MD, Rubio S, Pérez-Bendito D. Assessment of the surfactant-dye binding degree method as an alternative to the methylenblue method for the determination of anionic surfactants in aqueous environmental samples. Anal Chim Acta. 2007;588(2):252–60.
- Costi EM, Sicilia MD, Rubio S, Pérez-Bendito D. Quantitation of fusidane antibiotics in pharmaceuticals using the surfactant–dye binding degree method. Anal Chim Acta. 2005;549(1–2):159–65.
- Pedraza A, Sicilia MD, Rubio S, Pérez-Bendito D. Surfactant–dye binding degree method for the determination of amphiphilic drugs. Anal Chim Acta. 2004;522(1):89–97.
- Costi EM, Sicilia MD, Rubio S, Pérez-Bendito D. Determination of cationic surfactants in pharmaceuticals based on competitive aggregation in ternary amphiphile mixtures. Anal Chim Acta. 2006;577(2):257–63.
- Khan H. Analytical Method Development in Pharmaceutical Research: Steps involved in HPLC Method Development. Asian J Pharm Res. 2017;7(3):203–7.
- Gahart BL, Nazareno AR. Gahart’s 2018 Intravenous Medications: A Handbook for Nurses and Health Professionals. Elsevier Health Sciences;2017.
- Al-Ghobashy MA, Mostafa MM, Abed HS, Fathalla FA, Salem MY. Correlation between dynamic light scattering and size exclusion high performance liquid chromatography for monitoring the effect of pH on
- stability of biopharmaceuticals. J Chromatogr B. 2017;1060:1–9.
- Lebiedzińska A, Marszałł ML, Kuta J, Szefer P. Reversed-phase highperformance liquid chromatography method with coulometric electrochemical and ultraviolet detection for the quantification of vitamins B1 (thiamine), B6 (pyridoxamine, pyridoxal and pyridoxine) and B12 in animal and plant foods. J Chromatogr A. 2007;1173(1–2):71–80.
- Szabó T, Tombácz E, Illés E, Dékány I. Enhanced acidity and pH-dependent surface charge characterization of successively oxidized graphite oxides. Carbon N Y. 2006;44(3):537–45.
- Agrawal S, Ashokraj Y, Bharatam P V, Pillai O, Panchagnula R. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur J Pharm Sci. 2004;22(2–3):127–44.
- Gilchrist SE, Letchford K, Burt HM. The solid-state characterization of fusidic acid. Int J Pharm. 2012;422(1–2):245–53.
- Sarkar M, Perumal OP, Panchagnula R. Solid-state characterization of nevirapine. Indian J Pharm Sci. 2008;70(5):619.
- Manfio ML, Agarrayua DA, Machado JC, Schmidt CA. A fully validated microbiological assay to evaluate the potency of ceftriaxone sodium. Brazilian J Pharm Sci. 2013;49(4):753–62.
- Ramautar R, Somsen GW, de Jong GJ. CE‐MS for metabolomics: developments and applications in the period 2012–2014. Electrophoresis.2015;36(1):212–24.
- Pembrey RS, Marshall KC, Schneider RP. Cell surface analysis techniques: what do cell preparation protocols do to cell surface properties? Appl Environ Microbiol. 1999;65(7):2877–94.
- Thomas V, Yallapu MM, Sreedhar B, Bajpai SK. A versatile strategy to fabricate hydrogel–silver nanocomposites and investigation of their antimicrobial activity. J Colloid Interface Sci. 2007;315(1):389–95.
- Pauli GF. qNMR—a versatile concept for the validation of natural product reference compounds. Phytochem Anal an Int J Plant Chem Biochem Tech. 2001;12(1):28–42.
- Zuluaga AF, Agudelo M, Rodriguez CA, Vesga O. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clin Pharmacol. 2009;9(1):1–11.